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ABSTRACT
The development of a strategy to improve oxygen delivery to cells seeded on scaffolds is
essential for the success of tissue engineering applications. The focus of this work was to
explore

the

application of

cyclodextrin inclusion complexes

(CD:ICs)

with

perfluorocarbons as oxygen carriers. CD:ICs were prepared from alpha-cyclodextrin and
perfluoroperhydrophenanthrene via co-precipitation, paste mixing, and dry mixing
complexation techniques. Characterization indicated that paste mixing at a 2:1 host:guest
ratio was the most effective method for complexation between the parent molecules. The
CD:ICs were then successfully incorporated in 3D fibrous mats via electrospinning with
poly(carbonate urethane) and polycaprolactone as biostable and biodegradable polymer
matrices, respectively. Electrospinning conditions were optimized to achieve appropriate
fiber morphology for tissue engineering applications and material characterization
indicated some of the CD:ICs were present on the fiber surface. The dissolved oxygen
concentration increased significantly in the presence of either CD:ICs or CD:ICfunctionalized fibrous mats at various conditions in model solutions. Overall, this study
demonstrates that CD:ICs prepared with perfluorocarbons are potential oxygen carriers,
and when embedded in scaffolds they may present a viable approach to enhancing oxygen
delivery to cells seeded on tissue engineering scaffolds.
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1 INTRODUCTION
1.1 Scope
Tissue engineering continues to emerge as a strategy for the repair and regeneration of
diseased or damaged tissues and organs as an alternative to current therapies. 1 Scaffoldguided tissue engineering involves seeding cells onto a porous three-dimensional (3D)
scaffold that supports in vitro tissue formation and maturation. The resulting engineered
tissue is envisioned to be implanted in a patient where it further grows, going through selfrepair remodeling. The ultimate objective of tissue engineering is thus to develop
responsive living tissues with properties similar to those of the native tissues they are
intended to replace, and can be applied to many, if not all, tissues in the body. However,
one of the major factors hindering the success of scaffold-guided tissue engineering is the
inability to deliver sufficient oxygen to the growing constructs in vitro. Previous attempts
to overcome this limitation have been riddled with drawbacks; so the task remains a
fundamental consideration for fabricating engineered tissues.2-4

Oxygen delivery, in particular, is a limiting step for developing tissues of a clinicallyrelevant size because of the low solubility of oxygen in culture media, which is further
exacerbated by the high oxygen requirements for cells, which consume five to six moles
of oxygen per mole of monosaccharide.5 Clearly, the delivery of oxygen to cells requires
the development of an oxygen delivery system that is more efficient than molecular
diffusion alone. When designing an alternative oxygen delivery strategy, arguably the most
important factor is the length of and extent of delivery with the goal of continuous and
sustained delivery such that sufficient quantities are available until the cells seeded on the
scaffold are adequately matured into clinically-relevant thick tissues. If the developed
strategy involves altering the scaffold in some way, it must be done such that the scaffold
properties, particularly porosity and morphology, are not adversely affected. Finally, it is
imperative that the materials used are cytocompatible and do not introduce any toxic or
otherwise harmful by-products.

2
In this work, cyclodextrin inclusion complexes were prepared with a perfluorocarbon, and
explored for their ability to enhance oxygen delivery when embedded in tissue engineering
scaffolds.

1.2 Thesis Outline
In view of the scope described above, the work presented in this thesis underscores the
importance of addressing oxygen delivery limitations in fabricating engineered tissues of
clinical relevance. Firstly, Chapter 2 provides an in-depth literature review covering
pertinent information related to the topics being discussed, specifically tissue engineering,
oxygen mass transfer in tissues, the chemistry of perfluorocarbon compounds, and
cyclodextrin inclusion complexes. This thesis is separated into three main objectives, with
all materials and methods, including experimental parameters, presented at the beginning
of each chapter. Chapter 3 describes the initial objective of preparation and characterization
of cyclodextrin inclusion complexes with perfluorocarbons. Chapter 4 describes the
fabrication and characterization of tissue engineering scaffolds incorporating the prepared
cyclodextrin inclusion complexes. Chapter 5 describes the in vitro analysis of oxygen
delivery for both the cyclodextrin/perfluorocarbon inclusion complexes and the
functionalized three dimensional scaffolds. Finally, Chapter 6 provides a general
conclusion of the major findings in this study, its strengths and limitations, and future
directions.
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2 LITERATURE REVIEW*
2.1 Tissue Engineering
Tissue engineering is the assembly of cells and their support structures for the repair and
regeneration of diseased or damaged tissues and organs as an alternative to current
therapies.1 One strategy of tissue engineering (Figure 2-1), involves seeding cells onto a
porous three-dimensional (3D) scaffold that supports in vitro tissue formation and
maturation. The resulting engineered tissue is implanted in a patient where it further grows,
through self-repair remodeling. The ultimate objective of tissue engineering is thus to
develop responsive living tissues with properties similar to those of the native tissues they
are intended to replace, and can be applied to many, if not all, tissues in the body. Not
surprisingly, tissue engineering continues to be a promising alternative to current
treatments for diseased and damaged organs, and it has already found applications in a
variety of other areas such as drug research and discovery.2-4 The strategies of tissue
engineering are conceptually simple and appealing yet they have proven to be challenging
engineering tasks. Despite rapid advances made in this field,5, 6 success is still limited due
to significant knowledge gaps in the ability to control, coordinate, and direct tissue
formation, which are the ultimate goals for tissue engineering.

Scaffolds
With the few exceptions,7-9 exogenous porous 3D scaffolds which mimic the extracellular
matrix (ECM) are required for the growth of cells to form an engineered construct.10, 11
Depending on the intended application, scaffolds may be designed to be biodegradable so
that only the neo-tissue will remain after a given period of culture time or following
implantation, or they may be biostable such that a composite tissue that provides long-term
support could be fabricated.12-15 In the case of biodegradable scaffolds, cells will remodel
the scaffold with their own ECM proteins creating the intended tissue without

*

Parts of this chapter have been published: Tierney GB Deluzio, Dawit G Seifu, Kibret Mequanint, 3D
scaffolds in tissue engineering and regenerative medicine: beyond the structural templates? Pharmaceutical
Bioprocessing 2013, 1(3), 267-281.
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Figure 2-1: Schematic diagram showing the essential stages of scaffold-guided tissue
engineering
compromising the tissue structural integrity. This, however, requires strict coordination of
the scaffold biodegradation rate with the biosynthetic rate and is one of the major obstacles
in the field today. In addition, a scaffold must have several required characteristics:
biocompatibility, appropriate mechanical strength and compliance, optimal porosity for
cell seeding, in vitro nutrient and oxygen transport, and the ability to bind to cells and
release growth factors when needed. Although some of these criteria could be met with
existing scaffolds, they do not always provide biological cues for embedded cells and do
not interact with the cells. In the body, cells reside within the ECM, which provides tissues
with the appropriate architecture as well as signaling cues that influence key cell function
such as adhesion, migration, proliferation, differentiation, and secretion of ECM
components.16 Fabrication of tissues in vitro thus requires that cells be given a more

6
specific level of instruction so that tissue regeneration in the host is successful. With the
discovery of cell adhesion peptide domains in fibronectin, collagen, and laminin, the design
of synthetic extracellular matrices with biological activity has become a valuable strategy
to impart biomimetic properties.17-19

The selection of scaffold type and material depends on the specific tissue engineering
application, as well as the applicable design criteria. Natural materials such as collagen,20
chitosan,21 and hyaluronic acid22 have the advantage of being generally nontoxic in
addition to providing biological cues to promote cell attachment and proliferation.
However, these natural materials are difficult to fabricate due to their limited processing
parameters and often result in constructs with poor mechanical properties. Synthetic
materials, on the other hand, are readily available and generally easy to modify, with
minimal batch to batch variations. However, they do not innately possess appropriate sites
to enhance cellular interactions and therefore lack bioactivity. The method of scaffold
fabrication also significantly impacts the physical and chemical properties of the resulting
tissue engineered construct. Other aspects, including reproducibility and costeffectiveness, should also be considered when selecting materials and fabrication
techniques. Common methods for scaffold fabrication include solvent casting/particulate
leaching and electrospinning, with more advanced techniques, such as rapid 3D plotting,
solid free form, and 3D projection stereolithography, being developed.23-26 Since the work
in this thesis utilized electrospinning to fabricate scaffolds, a succinct review of the
electrospinning process is described in the following section (2.1.1.1).

2.1.1.1 Electrospinning
One of the most commonly utilized methods for scaffold fabrication is electrospinning.
Electrospinning was initially developed in 1902,27, 28 and it has been applied to fabricate
tissue engineering scaffolds since the mid-1990s. Electrospinning is a versatile technique
that enables the production of multi-functional fibers in the nano- to micrometer range from
a wide variety of materials including but not limited to polymers, polymer blends, sol-gels,
composites, and ceramics.29-31 In general, electrospinning is a relatively simple, versatile,
and cost-effective method. The typical electrospinning setup consists of a syringe pump, a
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high voltage source, and a collector (Figure 2-2). The selected polymer is dissolved in a
solvent and the resulting polymer solution is loaded into a syringe. A strong electrostatic
force is applied to the needle tip via a high voltage supply, inducing a charge in the solution.
As the polymer solution is forced through the syringe via the syringe pump, the charge
induced within the polymer begins to overcome the surface tension holding the polymer
solution suspended at the needle tip. The solution at the tip begins to elongate and form a
conical shape known as a Taylor cone.28, 32, 33 When the critical value at which the surface
tension is overcome is reached, the solution is ejected from the tip of the Taylor cone as a
charged jet.32, 34, 35 The solvent evaporates during the flight of the jet in air across the
distance between the needle tip and collector, resulting in the continuous accumulation of
solid polymer fibers in a non-woven arrangement on the grounded collector. The collector
can be one of several configurations, including a stationary plate or a rotating mandrel. 27,
28

The electrospinning jet is composed of four regions: the base, jet, splay, and collection. 36

In the first region, the base, the jet emerges to form the Taylor cone. The polymer jet is
then accelerated and stretched by the electric forces, decreasing its diameter and increasing
the charge density. The jet then appears to splay into many small fibers of approximately
equal diameter, yet the jet is actually a single, rapidly whipping jet that undergoes bending
and stretching.32, 35 The fibrous mats that result from electrospinning possess important
characteristics for tissue engineering scaffolds. These characteristics include a large
surface-to-volume ratio, pore sizes and fibers in the nano-range, and an interconnected
structure,36 and make the fibrous configurations that result from electrospinning useful in
mimicking of the ECM. Electrospinning is generally a simple and cost-effective technique.
Furthermore, it is relatively simple to incorporate various additives during the
electrospinning process in order to improve on the functionality of the fibers. 29, 31 The main
disadvantage of electrospinning is that the small pore spacing leads to difficulties with cell
infiltration during cell delivery and fostering; however, electrospun nanofibers best mimic
several ECM proteins.37, 38
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Figure 2-2: Schematic of electrospinning set-up
The characteristics of the resultant fibrous mats can be controlled by a number of
parameters: solution properties, controlled variables, and ambient parameters. 32, 36 The
solution properties include viscosity, conductivity, surface tension, polymer molecular
weight, dipole moment, and dielectric constant of the polymer solution. It is difficult to
determine the effect of individual solution properties as they are usually connected and are
therefore difficult to isolate. Nevertheless, the viscosity of the solution, as controlled by
altering the polymer concentration, has a significant effect on the fiber size and
morphology; they are directly proportional, with fiber diameter generally increasing as
solution viscosity is increased. At very low viscosities, there are not enough chain
entanglements and overlapping to create a stable jet, so the process is characteristic of
electrospraying, yielding beads or fibers possessing defects such as beading. 39 Increasing
the molecular weight of the polymer also decreases the number of beads and droplets
formed on the fibers.36 Increasing the conductivity of the solution generally decreases
beading, resulting in more uniform and smaller fibers. The controlled variables include
flow rate, electric field strength, distance between tip and collector, needle tip design, and
collector composition and geometry. Decreasing the flow rate generally results in fibers
with smaller diameters, as flow rate and fiber diameter are directly proportional. If the flow
rate is too high, the wet fibers will not have enough time to dry before reaching the
collector, resulting in beading and fiber fusion. Similarly, there is a minimum distance
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between the needle tip and collector required in order to give the fibers enough time to dry,
with beading observed at distances that are too close or far. In general, increasing the
voltage also causes an increase in beading. Overall, fiber diameter is inversely proportional
to both distance and electric potential.36 Furthermore, a solvent with suitable volatility
should be selected to facilitate sufficient evaporation over the allocated needle tip to
collector distance.35

Incorporating cyclodextrins (CDs) or their inclusion complexes (ICs) into an electrospun
mat can impart unique characteristics to the fibers, creating interesting functionality, and
potentially improving the application of cyclodextrin and/or electrospun fibers. 31 A number
of studies have explored the functionalization of electrospun nanofibers with CDs
incorporated for a variety of applications, for example poly(methyl methacrylate)
containing CD-menthol-ICs,29 polystyrene fibers containing CD-menthol-ICs,40 polyvinyl
alcohol nanofibers incorporating CD-vanillin-ICs,41 polystyrene incorporating CDs as
molecular filters,42 and polyacrylonitrile with silver/β-CD nanoparticles.30 Moreover,
polymer-free nanofibers have been prepared by electrospinning cyclodextrin, its
derivatives, and their inclusion complexes alone. 39 For instance, polymer-free nanofibers
have been obtained from hydroxypropyl-β-cyclodextrin and its inclusion complexes with
triclosan, and the resulting fibrous mats possess some mechanical integrity and can be
handled and folded as a free-standing web.43 The success of this procedure is dependent
upon considerable aggregates and adequate interactions between the CD molecules,
effectively acting as chain entanglements in the solution in order to create a stable jet. 39
Cyclodextrin has been shown to positively affect the electrospinning of polymer solutions.
The addition of CD increases the conductivity of the polymer solution, allowing for
successful electrospinning of bead-free fibers from low polymer concentrations.29, 40 This
is because the polymer solution is subjected to higher stretching under the high electric
field.31 The addition of CD can also influence the viscosity of the polymer solution,
potentially furthering the effect of CD on fiber morphology. However, in the case of
electrospinning polyvinyl alcohol with a CD-vanillin-ICs, the conductivity of the resulting
polymer solution was lower, resulting in less stretching of the electrified jet, and in turn
thicker fibers, contradictory to the general observed trend. 41
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2.2 Oxygen Mass Transfer in Tissues
The Challenges of Oxygen Transfer in Engineered Tissues
The success of engineered tissues has been limited by the inability to deliver sufficient
oxygen to the growing constructs. Oxygen delivery, in particular, is a limiting step for
clinically-relevant size tissues because of its low solubility in culture media.44 This is
further exacerbated by the fact that cells consume five to six moles of oxygen per mole of
monosaccharide according to the following mole balance.
C6 H12 O6 +6O2 →6CO2 +6H2 O

(2-1)

Clearly, the delivery of this much oxygen to cells requires the development of an oxygen
delivery system that is more efficient than molecular diffusion alone. 45

The lack of sufficient oxygen supply to cells is exemplified by results showing cellular
spheroids containing a hypoxic and necrotic center surrounded by a rim of viable cells.46,47
This is because the cells located in the center of the tissue engineered constructs experience
different environmental conditions than those located at the peripheral boundaries. 48 It has
been shown that oxygen concentrations decline rapidly from the exterior to the interior
within the structure and that the oxygen gradients are more pronounced during the early
stages of tissue development.48 In addition to cellular necrosis, insufficient oxygen levels
result in a shift to anaerobic metabolism and energy conservation. 49 For the tissue
engineering approach to become a clinical success, it is vital that the challenge of delivering
sufficient oxygen to cells seeded on scaffolds is overcome.

In vivo Oxygen Transfer
In the body, oxygen is supplied in sufficient amounts via two specialized systems:
convection and hemoglobin. Firstly, the circulatory system enhances the delivery of
oxygen to vascularized tissues via convection of blood through the capillary network which
has the effect of decreasing the distance required for diffusion. Furthermore, hemoglobin,
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a natural oxygen carrier protein, overcomes the very low solubility of oxygen in plasma by
carrying 65 times more oxygen than blood plasma alone. 50

Alternative Oxygen Delivery Strategies
The delivery of nutrients and the removal of metabolic waste materials remains to be a
fundamental consideration for fabricating engineered tissues. 51,

52, 53

A number of

approaches have been developed to improve the delivery of oxygen to cells seeded on
tissue engineering constructs, as summarized in Figure 2-3, adapted from Malda et al.48
This section evaluates a few such studies with the intent of bringing attention to the
limitations of current strategies and rationale for this research.

One approach to reducing hypoxia in vitro is the use of perfusion bioreactors where oxygen
dissolved in the culture medium diffuses to the scaffold interior. For this purpose,
bioreactors have been developed with the intent to mechanically stimulate the growing
tissue constructs with physiologically relevant forces and to improve mass transfer within
the tissue. Although the former is largely successful, the latter has shown to be a formidable
engineering task. Therefore, the delivery of nutrients and the removal of metabolic waste
materials remained to be a fundamental consideration for fabricating engineered
tissues.52,54,55

In the case of flow-induced mass transfer, the high flow rate required to maintain an
adequate oxygen concentration for cell viability often surpasses the shear stress tolerance
of the cells.56 Alternatively, one feasible approach involves the use of perfluorocarbon
(PFC) emulsions as an oxygen carrier emulating the role of hemoglobin in the physiologic
system.52 PFCs have a high dissolving power for oxygen and are hydrophobic, lipophobic,
and stable which makes them generally biologically compatible. However, unlike oxygen
chemically bound to hemoglobin, solubilized oxygen can be rapidly and extensively
extracted from PFC molecules.57 As oxygen is depleted from the culture medium, it is
replenished via diffusion of dissolved oxygen from the PFC particles. 52 The oxygen
unloading of the PFC emulsion is facilitated by its increased surface area. One
disadvantage of these emulsions is their lack of stability, resulting in stringent storage
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requirements and an overall lack of user-friendliness.57 Moreover, their high density causes
them to settle in the culture well or medium reservoir.50 From this, it can be inferred that
binding the oxygen carrier molecules to the scaffold would be advantageous.

Figure 2-3: Approaches to reduce hypoxia in vitro, promote
angiogenesis, or both after implantation of engineered tissues. Adapted
from Malda, J.; Klein, T.J.; Upton, Z., The roles of hypoxia in the in
vitro engineering of tissues. Tissue Engineering 2007, 13, (9), 2153-2162
with permission from Mary Ann Liebert, Inc.

One study aimed to closely mimic the biological environment by incorporating a parallel
array of channels within the porous 3D scaffold, representing the capillary network, and
supplementing the medium with a PFC emulsion, representing the hemoglobin.50 Porous
biorubber scaffolds, made of poly(glycerol-sebacate), were fabricated using a salt leaching
technique with sodium chloride as a porogen and an array of cubically packed parallel
channels was created using a computerized carbon dioxide laser system. Although it was
demonstrated that the channel walls were highly porous, as required for efficient nutrient
and oxygen transport, technical restrictions limited the size and spacing of the channels,
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resulting in channels that were much larger than the native capillaries. Increased
availability of oxygen resulted in significantly lower levels of lactate dehydrogenase, an
enzyme indicative of tissue breakdown signifying decreased cell death; increased DNA
content and cell density, indicating higher construct cellularity; and lower lactate to glucose
ratio, suggestive of more aerobic metabolism than the control. Electron microscopy of the
constructs following cell culturing showed that the channels remained open with cells
present between them; however, a compact and continuous tissue was not formed.
Moreover, settling of the PFC droplets was still evident within the experimental setup,
owing to the high density of the PFC emulsion, and the cells exhibited a rounded
morphology owing to the direct exposure to shear stress above their tolerance, due to the
perfusion culture conditions. As such, a number of the limitations associated with the
perfusion bioreactor and PFC emulsion strategies remained apparent with this technique. 50

Another method for improving the delivery of oxygen to cells is incorporating oxygen
generating chemicals into the 3D scaffolds. Calcium peroxide (CPO), which decomposes
in water to produce oxygen according to the following set of equations, was embedded into
poly(lactic-co-glycolic acid) (PLGA) scaffolds.
2CaO2 +4H2 O→2Ca(OH)2 +2H2 O2

(2-2)

2H2 O2 →O2 +2H2 O

(2-3)

The porous 3D PLGA constructs were prepared via particulate leaching with paraffin as a
porogen and contained CPO at concentrations of 0, 1, 5, and 10 wt. %. Scanning electron
microscopy data suggested that the pore size and porosity of the scaffold were unaffected
by the incorporation of CPO and the scaffold maintained a highly porous and open pore
structure. To test the effect on oxygen delivery, NIH3T3 fibroblasts were seeded onto
PLGA and PLGA-CPO scaffolds with the addition of catalase to capture the hydrogen
peroxide by-products that may be toxic to cells. Under normoxic conditions (21 % oxygen,
5 % carbon dioxide), significant cell viability with the incorporation of 5 % CPO was
shown. When scaffolds containing 5 % CPO were seeded with cells and cultured in a
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hypoxic environment (1 % oxygen, 5 % carbon dioxide), the metabolic activity on the
PLGA-CPO scaffold increased significantly compared with control scaffolds. The hypoxic
condition was chosen to test the oxygen generation from the CPO.58

A similar study of incorporating CPO into 3D polycaprolactone (PCL) nanofibers was
carried out to test the antibacterial properties of the calcium hydroxide produced during
oxygen generation.59 The reported results were not consistent with the previous study58
since the scaffolds were reported to be cytotoxic to human osteoblast cells. The
cytotoxicity, however, appeared to be temporary as cells regained a healthy status and
spread over the nanofiber mesh. This negative effect may be attributed to the initial burst
release of calcium hydroxide, suggesting that the effect may be transient, causing no longterm harm to tissue development.

As an alternative to calcium peroxide, sodium percarbonate (SPO) can be used as an
oxygen generating biomaterial. SPO decomposes in water according to the following
equations.60
[Na2 CO3 ]2 ∙ 3H2 O2 →4Na+ +2CO3 2-+3H2 O2

(2-4)

2H2 O2 →O2 +2H2 O

(2-5)

In a feasibility study, SPO was incorporated in a PLGA film using a solvent casting
fabrication technique. Oxygen was released steadily from the polymeric oxygen generating
(POG) film during the first 24 hours, after which it decreased until it reached complete
conversion at roughly 70 hours. Using a skin flap model in nude mice to study the effects
of the POG film, it was shown that necrosis was initially delayed for two days compared
to control models with PLGA-only films, yet after seven days the POG and control groups
were comparable. On a tissue level, exposure to the POG film resulted in significantly less
degradation, visible by a reduced amount of skin discolouration. This was further supported
by lower levels of lactate observed in POG groups, indicating that the cells were receiving
adequate oxygen to prevent anaerobic metabolism, as well as improved tissue strength as
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determined by biomechanical testing, indicating decreased degradation of ECM proteins.
It is logical that the beneficial effects are limited to the first two days as the majority of the
oxygen generation occurs during the first 24 hours. Evaluating oxygen delivery in an in
vivo model is crucial because the role that oxygen plays in tissue regeneration is complex
and varies between in vitro and clinical data.

The method of incorporating oxygen generating compounds, such as CPO and SPO, into
3D porous scaffolds shows potential for enhancing oxygen delivery to seeded cells.
However, calcium hydroxide and hydrogen peroxide are a strong base and oxidizing agent,
respectively which could be detrimental to cells seeded on the scaffolds. Inclusion of
catalase or ascorbic acid to protect against oxidative stress and remove potentially harmful
by-products could help to alleviate these effects. Based on the inconsistency in the reported
cytotoxicity of the by-products of the decomposition of CPO and SPO, further studies are
required to determine the amount of cell protector required to fully prevent toxic effects.
In addition, incorporating oxygen generating compounds delivers oxygen for a limited
time, until the oxygen generating compound is completely consumed. Further studies must
be done to determine if this is enough time to extend cell viability until tissue maturation
is established and if the amount of oxygen delivered could support larger constructs with
higher densities of cells.61

Clearly, one major drawback of directly incorporating the oxygen generating compound
into the tissue engineering construct is the rapid burst release resulting in enhanced oxygen
delivery over a short period as well as toxic amounts of hydrogen peroxide. In order to
overcome this limitation, the solid peroxide can be encapsulated within a hydrophobic,
biostable polymer that will restrict interaction with water, thereby modulating oxygen
generation. In one study, polydimethylsiloxane (PDMS) disks containing 25 % (w/w) CPO
powder were fabricated with the intent of enhancing cell viability within 3D tissue
engineered constructs.62 In an open system at 0.05 mM oxygen, the PDMS-CPO disks were
able to generate oxygen for approximately 40 days. The oxygen delivery potential of the
PDMS-CPO disks was tested by centrally incorporating the PDMS-CPO disks within 3D
agarose constructs containing varying cell densities of a β cell line, MIN6 cells, and
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culturing them under normoxic or hypoxic oxygen conditions (0.20 or 0.05 mM oxygen,
respectively) for three days. The cell viability was improved under hypoxic conditions with
the inclusion of the PDMS-CPO disk to the extent that the results were not statistically
significant to the corresponding normoxic group. It is likely that this improvement is not
as drastic under normoxic conditions because oxygen is no longer the limiting factor, rather
glucose availability or contact inhibition are preventing further increases in cell
proliferation. It was determined that the PDMS-CPO disks were most beneficial, in terms
of metabolic activity, at high cell loading densities, likely owing to the higher total rate of
oxygen consumption. As expected, a rim of live cells surrounding a core of dead cells was
evident on control constructs from live/dead confocal imaging. On the contrary, the live
and dead cells were intermingled throughout the CPO-containing construct and the necrotic
core was absent. Interestingly, when measurements were made three days after removing
the PDMS-CPO disk, results were statistically equivalent to the control group, reinforcing
the hypothesis that the observed improvement to cell viability was due solely to the
released oxygen.

A recent study in our laboratory tested the oxygen delivery capability of fluorinated porous
zeolite Y particles embedded into a 3D poly(carbonate urethane) (PCU) scaffold.61 The
zeolite

Y

particles

were

prepared

and

then

fluorinated

with

1H,1H,2H,2H-perfluorodecyltriethoxysilane resulting in fluorinated-zeolite (FZ) particles
with particle diameters between 850-1000 nm. Three dimensional PCU scaffolds
containing 2 wt. % embedded FZ particles were fabricated by the solvent casting and
particulate leaching method with NH4Cl porogens. Inclusion of greater than 2 wt. % FZ
particles was not possible due to insufficient mechanical integrity. Data confirmed that the
FZ particles were not leached out during the fabrication process. In addition, results
showed open and well-defined pores with high interconnectivity, uniform distribution of
FZ particles throughout the scaffold, and that the FZ particles were contained mostly at the
surface of the scaffold which is crucial for oxygen extraction by cells. This was important
for efficient cell infiltration and nutrient transport. To test the effect of the FZ particles on
oxygen delivery, human coronary artery smooth muscle cells (HCASMC) were seeded
onto the FZ modified and control scaffolds and were cultured for 4, 7, and 14 days. Cell
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number increased significantly after 4 and 7 days of culture on the PCU-FZ scaffolds
compared with control scaffolds likely attributed to increased oxygen delivery. Although
the HCASMC attached and spread on both control scaffolds, the infiltration depth was
double on the FZ modified scaffolds suggesting enhanced availability of oxygen at greater
depths in the scaffold.

Alternatively, oxygen delivery vectors can be prepared from cyclodextrin, cyclic
oligosaccharides made up of six to eight glucose units with a unique shape that allows them
to readily form inclusion complexes. Perfluorocarbon nanocapsules (PFC-NC) with a mean
diameter

of

350

nm

have

been

synthesized

from

perfluorodecalin

and

2,3-di-O-decafluorooctanoylcyclomaltooctaose (β-CD-𝐶8𝐹 ) as vehicles for oxygen
solubilization and delivery.63 The liberation of oxygen from the nanocapsules was
evaluated over a period of 24 hours following oxygenation of the PFC-NC suspension with
pure oxygen at 1 mL/min for 5 minutes. Compared to pure water oxygenized under the
same conditions, the PFC-NC showed both a delayed and prolonged release of oxygen.
However, no cell or scaffold studies have been carried out to date utilizing this biomaterial.
In comparison, PFC-NC must be oxygenated prior to use whereas FZ particles are able to
solubilize the oxygen when necessary according to Henry’s law. Since oxygen supply is
facilitated by the unloading of the oxygen molecule from the nanocapsule, the delivery is
not indefinite. Theoretically, however, the PFC-NC could be reloaded with oxygen, though
this is difficult to imagine as a realistic tissue engineering approach. PFC-NC require less
oxygenation than PFC emulsions and have the additional benefit of improved stability,
with the ability to be conserved for three months at 4 or 25 °C, thus overcoming one of the
main drawbacks of PFC emulsions, their lack of stability and resultant stringent storage
conditions.57 Since the particles are significantly smaller than the FZ particles, it can
reasonably be assumed that these molecules could be embedded in a 3D scaffold without
adversely affecting its properties.

As mentioned above, the delivery of oxygen to cells seeded on scaffolds is vital for
successfully developing tissues of clinical relevance. The preceding cited studies have
provided platforms to incorporate oxygen delivery vectors into 3D scaffolds without
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adversely affecting the porosity or morphology. An important factor is the length of the
oxygen delivery time provided by these vectors. Oxygen must be delivered to the cells
seeded on the scaffold in sufficient quantities until the engineered tissue matures.
Development of an improved method for oxygen delivery to cells, thereby preventing cell
necrosis would allow for enhanced tissue structures, ultimately leading to the fabrication
of clinically relevant tissues. Although the supply of oxygen to thick tissue constructs in
vitro (such as muscle and bone) can, in part, be addressed by strategies discussed above,
combination of these with prevascularization before transplantation is conceptually an
attractive approach. Such an approach relies on the seeding of endothelial cells to form
primitive capillary-like tubes within the constructs that may improve the vascularization,
blood perfusion, and survival of the tissue constructs after transplantation.64,

65

Both

naturally occurring and synthetic scaffolds that were prevascularized appeared to have
better host integration and vascularization in animal experiments compared with control
scaffolds.65-67 It is, however, not clear if the in vivo vascular networks formed are nascent
with invested pericytes and/or smooth muscle cells. Despite this, it is likely that these
emerging data and shared strategies accelerate functional tissue fabrication and host
integration.

2.3 The Chemistry of Perfluorocarbon Compounds
The search for alternative oxygen binding chemicals has been and remains to be an active
area of research.68 From a clinical standpoint, this search has been fuelled by increasing
negative public perceptions about blood safety coupled with the potential risk of
transmitting diseases through transfusion.69, 70 There are two general categories of current
approaches for developing alternative oxygen binding chemicals, those based on
hemoglobin and those based on perfluorinated compounds. Products based on hemoglobin
include modified hemoglobin derived from either human or animal sources, or genetically
engineered recombinant microorganisms and plants.71-73 Perfluorinated compounds, on the
other hand, have been synthesized as emulsions because PFC liquids are immiscible with
aqueous systems, including blood and other body fluids. 73 Oxygent™ (Alliance
Pharmaceutical Corp., San Diego, CA), for example, is an improved second-generation
perfluorocarbon emulsion based on perflubron (perfluorooctylbromide, C8F17Br) that is
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highly stable and can carry over twenty times more oxygen than plasma. 74
Perfluorocarbons are organic molecules where the carbon network is surrounded entirely
by fluorine atoms. Because fluorine has a much denser electron cloud, a significantly larger
electron affinity, and a lower polarizability than hydrogen, in addition to being the most
electronegative atom, the resulting perfluorinated molecules are quite different than their
hydrogen analogues. The larger, electronically denser fluorine atoms cover and protect the
carbon backbone much more effectively than hydrogen atoms. The extreme electron
attracting character of fluorine enhances the C─C bond energy in the skeleton by shrinking
the orbitals of the carbons. Moreover, the match between the carbon and fluorine orbitals
is superior to that of carbon and hydrogen; in fact, it is the strongest single bond found in
molecular compounds (approximately 530 kJ/mol).68, 75 The larger fluorine atom is space
demanding, forcing the carbon skeleton to adopt a helical rather than zig-zag arrangement.
As well, the bulkiness makes the perfluorinated chains more rigid and allows for fewer
kinks. This steric shielding results in PFCs being inert as there are no low energy molecular
orbitals accessible for reaction.76 Overall, the excellent steric and electronic protection the
fluorine atoms confer on the carbon skeleton make PFCs both chemically and
thermodynamically stable.76

Oxygen Solubility in PFCs
PFCs do not chemically bind to gases, but they have the ability to dissolve large quantities
of non-polar gases such as oxygen and carbon dioxide. This ability is due to the extremely
low polarizability of fluorine which translates into low van der Waals forces within the
PFC liquid because van der Waals interactions depend on fluctuations in polarity of the
electronic cloud. As van der Waals interactions are the only intermolecular forces that keep
non-polar molecules together, in PFCs they are weak, in sharp contrast with the strong
intramolecular bonds. Gas dissolution, therefore, is a passive process whereby the gas
molecules occupy “cavities” within the intermolecular spaces of the PFC liquid.76, 77

Oxygen carrying by PFCs is dissimilar to that of hemoglobin where the oxygen is
chemically bound via a strong, localized chemical coordination bond between the dioxygen
molecule and the iron atom of the hemoglobin molecule. 78 Therefore, oxygen unloading
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from PFCs is enhanced significantly by the lack of chemical fixation and occurs roughly
twice as fast as from hemoglobin,70 providing immediate availability to tissues. The
difference in the interactions of oxygen with hemoglobin and PFCs is reflected in the
difference in oxygen uptake profiles as a function of partial pressure (pO2) which is
sigmoid for hemoglobin and linear for PFCs. The linearity of the oxygen uptake profile for
PFCs is the result of Henry’s law in which solubility (c) is directly proportional to the gas
partial pressure (p),73 shown in the following equation where kH is a Henry’s law constant.
𝑝 = 𝑘𝐻 𝑐

(2-6)

Linear PFCs, such as perflubron, dissolve oxygen more effectively than cyclic molecules,
such as perfluorodecalin. In general, oxygen solubility in a PFC is inversely proportional
to the molecular weight and directly proportional to the number of fluorine atoms, with a
typical value of 45 mL/100 mL at standard conditions, 75 roughly 20-25 times greater than
in either water or blood plasma under the same conditions.

PFCs for Enhanced Oxygen Delivery
In addition to being chemically unreactive, PFCs are also biologically inert. This is enabled
by both their hydrophobicity and lipophobicity, such that they are not soluble in either the
aqueous phase or lipids, and are therefore immiscible with body fluids and do not diffuse
into interstitial fluids.78 Furthermore, they are not metabolized in the body as there are no
enzymes capable of recycling them thus they do not present any metabolite-related toxicity,
and are excreted primarily as a vapour through the lungs.77 Intravenous-administered PFC
droplets are also cleared from the circulation by phagocytic cells of the monocytemacrophage system.73 Pure PFCs do not have any negative effects on cell cultures, simply
benefits resulting from their ability to enhance oxygen delivery, but PFC emulsions can
have toxic effect due to the emulsifiers used.76 The lack of toxicity and negative side effects
of liquid PFCs on living cells has been confirmed by in vitro experiments and also in
clinical investigations.79-82 Other characteristics that make PFCs suitable for biological
applications is that they are sterilizable, for example by autoclaving, and carry no risks of
infection.57 In order to be utilized for oxygen delivery, they must have rapid excretion,
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preferably a few days and no longer than a few weeks, 57 and the ability to be easily
synthesized on a large scale in a highly pure form at a reasonable price. 78 The greatest
disadvantage of using PFC emulsions is their lack of stability, resultant stringent storage
requirements, and overall lack of user-friendliness.57

In order to utilize PFCs as oxygen vectors in vivo, they must be emulsified into a stable,
injectable, and small emulsion. They can then be injected intravascularly, increasing the
oxygen solubility in the plasma phase. Perflubron and perfluorodecalin are the two
compounds most widely evaluated as the principal constituents of injectable PFC
emulsions. Both compounds have molecular weights within the range 460-500 g/mol,
which is recognized as giving acceptable tissue retention times, and can be manufactured
to a high degree of purity.77 Clark and Gollan83 were the first to demonstrate that mice
could live while breathing an O2-saturated liquid PFC without any harm to the animals.
The first preparation of a physiologically adjusted PFC emulsion was reported by Sloviter
and Kamimoto using bovine serum albumin as a surfactant. 84 There is also growing interest
in the use of PFCs for regulating oxygen supply to cultured cells with the potential to reduce
or eliminate cellular damage caused by conventional, vigorous aeration methods. 85 PFCs
are especially advantageous for use in cell and tissue culture systems since they are heat
stable, readily sterilized, and can be recovered from aqueous systems with the potential for
recycling, thus making them economically viable, and have been used as oxygen vectors
for both mammalian and insect cells grown in vitro.73, 85, 86 Specifically, in cardiac and
tracheal tissue engineering, PFCs have been shown to improve oxygenation of tissue
engineered constructs without adverse effects. 50, 52, 87 The major limitation in this area of
application, however, is droplet settling in culture wells or medium reservoirs due to their
high density.57

2.4 Cyclodextrin Inclusion Complexes
Cyclodextrins
Cyclodextrins, also known as cycloamyloses, cyclomaltoses, or Shardinger dextrins, are
cyclic oligosaccharides containing six (α-CD), seven (β-CD), or eight (γ-CD) linked
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glucopyranose units. Due to steric factors, cyclodextrins built from less than six
glucopyranose units do not exist; however, cyclodextrins with greater than eight
glucopyranose units have been synthesized.88, 89 Due to their molecular structure and the
lack of free rotation about the bonds connecting the glucopyranose units, CDs have a
unique toroid or truncated cone shape (shown in Figure 2-4). The hydrophilic hydroxyl
groups are located on the outer surface, with the primary and secondary hydroxyl groups
located on the narrow and wide side, respectively.90 This structure renders the CDs watersoluble and concurrently generates a hydrophobic inner cavity. 89, 91 CDs are capable of
accommodating a variety of molecules entirely or partially within their cavity, forming a
non-covalent host-guest system known as an inclusion complex.

CDs are produced by the enzymatic degradation of starch, a renewable material derived
from potatoes, corn, rice, etc.39, 89 When the amylose fraction of starch is degraded by
glucosyltransferases, one or several turns of the amylose helix are hydrolyzed off and their
ends are joined together, thereby producing the cyclic oligosaccharides. 91 CDs are
produced in amounts of thousands of tons per year using environmentally friendly
technologies, with prices at levels acceptable for most industrial purposes. 88 CDs are
widely accepted as having low toxicity both orally and intravenously. Orally administered
CDs have been shown to be harmless because only insignificant amounts are absorbed; 92,
93

and unmodified CDs are completely resistant towards β-amylase, and α-amylase is

capable of hydrolyzing CDs only at a slow rate. 94 After intravenous injections, CDs are
mainly excreted in their intact form by renal filtration as they are minimally susceptible to
hydrolytic cleavage or degradation by human enzymes. 89 In general, CDs are only able to
permeate lipophilic biological membranes with considerable difficulty.95 Although tests
showed that cyclodextrins cannot be considered toxic due to extremely high LD 50 values,
at very high concentrations CDs can extract cholesterol and other lipid membrane
components from cells, leading to the disruption of cell membranes. 89, 92, 96
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α-CD

β-CD

γ-CD

Figure 2-4: Molecular structure and toroidal shape of cyclodextrin molecules

Because they are natural and relatively non-toxic, have a low price and are commercially
available, and possess the ability to form inclusion complexes with a wide range of guest
molecules, CDs have been applied to many areas including but not limited to
pharmaceutical,97,

98

food,40,

99

cosmetic,100,

101

and textile industries.102,

103

Their

significance in pharmaceuticals alone is well evidenced by the increasing number of
marketed or approved medicinal products containing CDs.104 Furthermore, the
functionalization of fibers with CD and/or its inclusion complexes leads to fibrous mats

24

with unique characteristics, potentially broadening the application areas of both
cyclodextrins and nanofibers.29

Inclusion Complexes
Arguably the most interesting property of CDs is their ability to form inclusion complexes,
a unique form of chemical complex, with a variety of solid, liquid, and gaseous guest
molecules.95 The formation of cyclodextrin inclusion complexes (CD:ICs) depends largely
on the agreement between the dimensions of the cyclodextrin cavity and the guest
molecule, with the guest molecule apparently striving to fill up the cyclodextrin cavity. 92,
105

If the guest is the wrong size, it will not fit properly into the cyclodextrin cavity. 95

Molecules of a very small size will not form stable complexes with cyclodextrins as they
will slip out of the cavity. Moreover, molecules that are too large or bulky will also not
form inclusion complexes with cyclodextrins. Nevertheless, if certain functional groups or
side chains of the molecule can penetrate the CD cavity then partial complex formation is
possible. Most frequently, complexes are formed at a 1:1 CD:guest ratio, although if a guest
is too long to be completely enclosed by one CD cavity, multiple CDs can be threaded onto
the guest creating 2:1, 3:1, etc. (CD:guest) ratios92, 94 Furthermore, in the case of some low
molecular weight molecules, more than one guest may fit into the cavity. 95 The mechanism
of complex formation is depicted in Figure 2-5 for CD:ICs formed at 1:1 and 2:1 CD:guest
ratios. Due to the steric requirement of complexation, the different cyclodextrins show
different capabilities to form inclusion complexes with the same guest molecules. The
naturally occurring cyclodextrins have the same cavity depth (~7.8 Å), but the number of
glucose units determines the internal diameter of the cavity and its volume: α-CD, β-CD,
and γ-CD are roughly 6 Å, 7 Å, and 9 Å in diameter, respectively.29,

41, 95, 106

Some

properties and dimensions of CDs are shown in Table 2-1. The spatial requirements for
inclusion complex formation can be compared to the “lock and key” mechanism of enzyme
catalysis, where the substrate must be oriented properly with respect to the active centers
of the enzyme.106 Moreover, complex (CS) formation between the cyclodextrin (C) and
guest (substrate, S) components occurs according to the following equation, and can be
quantitatively described by the dissociation constant KD.92
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KD

C+S ↔ C∙S
KD =

[C]∙[S]
[C∙S]

(2-7)
(2-8)

In solution, the process by which an inclusion complex is formed occurs according to a
number of distinct steps.94, 107 Initially, the guest approaches the CD molecule and the water
structure breaks down, both inside the CD ring and around the guest, with the water
molecules entering the bulk solution. Next, the interactions between the guest molecule
and groups on the inner rim of the CD cavity are formed, including possibly hydrogen
bonds. Finally, the water structure is reconstructed around the complex and any exposed
parts of the guest. The thermodynamic interactions between the components of the system
are favourable for complex formation, creating a positive energetic driving force that pulls
the guest into the cyclodextrin cavity. Firstly, repulsive forces are decreased as the polar
water molecules are displaced from the apolar cyclodextrin cavity to join the larger pool,
and the number of hydrogen bonds formed increases. Secondly, there is a reduction in

(a)

+
(b)

Figure 2-5: Inclusion complex formation between cyclodextrin host and a guest
molecule (a) 1:1 CD:guest (b) 2:1 CD:guest
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repulsive interactions between the hydrophobic guest molecule and the aqueous
environment as it enters the cavity and increases the hydrophobic interactions. 95 These
driving forces do not exist in the dry, crystalline state, thus, isolating a product in solid
state is difficult.88

Table 2-1: Properties and dimensions of the naturally occurring cyclodextrins
Dimensions (Å)
Glucopyranose
Units

Molecular
Weight
(g/mol)

a

b

c

d

e

Cavity
Volume
(Å3)

α

6

972.84

14.6

5.3

4.7

13.2

7.9

174

β

7

1134.98

15.4

6.5

6.0

14.9

7.9

262

γ

8

1297.12

17.5

8.3

7.5

16.1

7.9

427

The inclusion complex is characterized by the absence of ordinary chemical bonds; the
interactions between the guest molecule and surrounding cyclodextrin are non-covalent
and generally weak. The interactions can be van der Waals, hydrophobic interactions,
dispersion forces, hydrogen bonding, electrostatic interaction, and steric effects. 92, 105, 106,
108, 109

In general, van der Waals forces predominate and include both permanent induced-

dipole-dipole interactions and London dispersion forces.92, 94, 95 Once inside the cavity, the
guest molecule may adjust its conformation in order to take maximum advantage of the
weak van der Waals forces that exist.95 Hydrophobic effects are involved because the guest
molecule replaces the enthalpy-rich, energetically unfavoured water molecules present in
the slightly apolar cyclodextrin cavity. If the complex is formed in solution, the liberated
water molecules are taken up by the bulk water where they can form more hydrogen bonds
than when contained in the cavity, and therefore gain degrees of freedom and contribute to
the stability of the complex owing to the resulting increase in entropy. 92, 94 Moreover, this
leads to a decrease of cyclodextrin ring strain, from the high energy conformation of the
CD-water complex to the lower energy conformation of the CD-guest complex, and an
apolar-apolar association, resulting in a more stable lower energy state overall. 94,

95

Depending on the guest molecule, the formation of hydrogen bonds with the CD hydroxyl
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groups can be involved.89,

94

The ion-dipole type of electrostatic interaction, between

undistorted charge distributions of the two molecules, can take place in CD complexation
because CDs are polar molecules, with modestly large dipole moments. 109

Once a complex has been formed and dried, it is stable and exhibits a long shelf life when
stored in dry conditions at or below ambient temperature. 95 Complex dissociation is
typically driven by a large increase in the number of water molecules in the surrounding
environment, frequently by dissolving a dried complex in water. 95 The resulting
concentration gradient shifts the equilibrium in Equation 2-7 to the left. Therefore, in
highly dilute and dynamic systems, such as the body, once the guest dissociates it has
difficulty finding another cyclodextrin to re-complex with and is left free in solution. For
this reason, the guest availability in the body is not hampered by slow release, but in fact,
it has been shown that the rates of formation/dissociation are close to diffusion controlled
limits.110 Moreover, complex dissociation can be triggered by an increase in temperature
which weakens the complex.92, 93 Because the normal body tissue temperature is roughly
37°C, the difference in temperature can contribute to guest dissociation in vivo.93
Furthermore, if the guest is lipophilic and has access to tissue but not cyclodextrin, the
tissue acts as a sink and causes dissociation of the complex based on simple mass action
principles.93

Inherent in the formation of a cyclodextrin inclusion complex is the covering of the guest
molecule either partially or entirely by cyclodextrin. This provides stabilization and
protection of the guest from evaporation, degradation, oxidation, etc., as well as alters
many of the physiochemical properties of the molecule. 41, 90 These physiochemical changes
facilitate the use of characterization techniques to confirm that the guest is indeed contained
within the cyclodextrin cavity. Cyclodextrin maintains some of its ability to form hydrogen
bonds with other molecules enabling them to remain at least partially water soluble in the
form of an inclusion complex.105 In fact, the ability to enhance the aqueous solubility of
highly insoluble drugs is one of the most studied applications of cyclodextrin inclusion
complexes along with controlled and/or delayed release of the drug. 40, 41, 95
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Complexes can be formed via a variety of techniques, and the selection is dependent on the
characteristic properties of each specific guest molecule and the equipment available. One
of the most commonly utilized techniques in the laboratory is co-precipitation, where the
guest is added to an aqueous solution of cyclodextrin with stirring. The inclusion complex
either precipitates out immediately or upon slow cooling and/or evaporation. The collected
precipitate may be washed, though this step is frequently detrimental to the complex.
Although the co-precipitation method works for a variety of guest molecules, it is difficult
to scale up due to the large quantity of water required. The main advantage is that complex
formation is visible by the disappearance of the guest. 92, 93, 95, 105, 111 Slurry complexation
involves less water than co-precipitation, suspending cyclodextrin at a 50-60% solids
concentration. The aqueous phase becomes saturated with cyclodextrin in solution and, as
guest molecules complex with the dissolved cyclodextrin, the complex will precipitate out
of the aqueous phase. More cyclodextrin dissolves, continuing to saturate the aqueous
phase, form the complex, and precipitate out of solution.93, 95, 111 Using even less water,
paste complexation involves adding a small amount of water to the cyclodextrin to form a
paste. The guest is added and they are mixed using a device such as a mortar in pestle, or
on a large scale using a kneader. This method is most suitable for industrial synthesis. The
resulting complex can be dried directly and milled to obtain a powder if a hard mass is
formed.92, 93, 95, 105, 111 Dry complexation, on the other hand, does not involve the use of any
water, the guest and cyclodextrin are simply mixed together. This method works best with
oils or other liquid guests. There is a risk of the mixing not being sufficiently thorough,
resulting in incomplete complexation.93, 95, 111 Less frequently used methods include damp
mixing and heating,93, 95 extrusion,93, 95 and layering.92

It is necessary to optimize the amount of water, degree and time of mixing, temperature
and heating time for each specific guest and complexation technique. Heat can be used to
increase the amount of CD dissolved, therefore increasing the probability of complexation,
providing the guest can tolerate the increased temperature. Additionally, heat can also
destabilize the complex, with most complexes beginning to decompose at 50-60 °C, though
heat stability varies with differing guests and some can be highly thermally stable. 95 For
this reason, if a solid complex is desired, care must be taken so as not to destroy the
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complex with heat during the drying process. For extremely delicate complexes, a
desiccator or freeze dryer may be used to dry the complexes in order to minimize the loss
of the volatile guest.95 Water is usually the preferred solvent for complexation techniques
due to the solubility of cyclodextrin, and also because water is easily displaced from the
cavity to make room for the guest molecule. However, not all guests are readily solubilized
in water and as a result, complexation can be very slow or impossible. In these cases, an
organic solvent can be used to dissolve the guest, but the solvent must not complex
preferentially with the cyclodextrin or have increased affinity for the guest, and must be
easily removed by evaporation.93 Furthermore, the use of too much solvent can cause the
guest to be so dilute that it does not come in contact with the cyclodextrin in a sufficient
amount to facilitate complexation. Moreover, some guest molecules, such as high
molecular weight oils, can preferentially associate with themselves rather than interact with
cyclodextrin. To counter this, the amount of solvent is increased, accompanied by sufficient
mixing in order to disperse and separate the guest molecules from each other. 95 Different
complexation techniques, such as paste or dry mixing could be more efficient for these
types of guest molecules.

Based on the complexation techniques, CD:ICs can exist in both solution and solid state,
with their structures differing significantly in each state. In solution, the formation of
inclusion complexes is not a fixed state but rather a dynamic equilibrium between
complexed and non-complexed guest molecules where the guest molecule continuously
associates and dissociates from the host.90, 93, 95 The guest is contained within the cavity,
and the entire complex is solvated by water molecules. On the other hand, in the crystal
state the guest may not be included within the cyclodextrin cavity but rather be enclosed in
a void space of a lattice or merely aggregate to the outside of the cyclodextrin, forming a
microcrystalline or amorphous powder.88, 90, 92 This arrangement can lead to the formation
of nonstoichiometric inclusion complexes.106 One of the benefits of preparing inclusion
complexes in solution is that more cyclodextrin molecules become available for
complexation whereas in the crystalline form only the surface molecules of the
cyclodextrin crystal are available for complexation. 95
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2.5 Rationale and Objectives of Study
Scaffold-guided tissue engineering continues to emerge as a strategy for the repair and
regeneration of diseased or damaged tissues and organs as an alternative to current
therapies.1 However, one of the major factors hindering the success of scaffold-guided
tissue engineering is the inability to deliver sufficient oxygen to the growing constructs.
Although numerous strategies have been developed to overcome this limitation, they have
been riddled with drawbacks; thus delivering sufficient oxygen remains a fundamental
consideration for fabricating engineered tissues. 51-53 One approach to improve oxygen
delivery to constructs is the use of perfusion bioreactors whereby oxygen dissolved in the
culture medium diffuses to the scaffold material. However, the flow rate required to
maintain an adequate oxygen concentration for cell viability often surpasses the shear stress
tolerance of cells.56 Alternatively, perfluorocarbons have been extensively explored as
oxygen carriers due to their high dissolving power for oxygen, though the focus has been
on fabricating perfluorocarbon emulsions which lack stability and are overall userunfriendly.57 Moreover, the high density of the emulsions causes them to settle in the
culture well or medium reservoir.50

By shifting the focus from PFC emulsions to alternative oxygen delivery strategies, some
of the drawbacks of first generation approaches can be remedied. A promising strategy
involves embedding oxygen generating compounds, such as calcium peroxide58 or sodium
percarbonate60 which decompose in water to produce oxygen, directly into the tissue
engineering scaffold. This approach has the advantage of providing oxygen throughout the
construct, notably in the center which is difficult to reach by diffusion alone, but it is limited
as the oxygen generating compound is eventually depleted. Tissue engineering scaffolds
incorporating fluorinated porous zeolite particles provide an alternative to this approach
whereby the embedded compound does not generate oxygen but enhances oxygen delivery
using the principles of oxygen solubility in PFCs.61

Cyclodextrins, cyclic oligosaccharides, have a unique shape that enables them to include a
wide range of guest molecules within their cavity forming an inclusion complex. In
addition, they are natural and relatively non-toxic, making them suitable for biological
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applications, and have a low price and are commercially available. 112 Because inclusion of
a guest molecule within the cyclodextrin cavity provides stabilization, it may serve to
overcome some of the shortcomings of PFC emulsions. Moreover, cyclodextrin inclusion
complexes have been incorporated into three-dimensional scaffolds via electrospinning;41,
42, 113

this immobilization of the CD:IC within the scaffold would impart enhanced oxygen

delivery throughout the construct, and delay or prevent settling of the PCFs in the culture
well or medium reservoir. Ultimately, the benefits of this approach would serve to enhance
oxygen delivery to the cells seeded on the construct, potentially facilitating the
development of thick constructs suitable for clinical applications.

It was hypothesized that cyclodextrin/perfluorocarbon inclusion complexes incorporated
into three-dimensional tissue engineering scaffolds would enhance oxygen delivery to
seeded cells. In view of the above rationale, the following objectives were formulated:


Prepare and characterize (FTIR, TGA, XRD) an inclusion complex from
cyclodextrin and a perfluorocarbon



Fabricate a three-dimensional scaffold containing the cyclodextrin inclusion
complex



Evaluate the ability of the cyclodextrin inclusion complex to act as an oxygen
carrier both on its own and when embedded in a scaffold
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3 PREPARATION AND CHARACTERIZATION OF
CYCLODEXTRIN INCLUSION COMPLEXES WITH
PERFLUOROPERHYDROPHENANTHRENE
Overview: This chapter discusses the preparation of a cyclodextrin inclusion complex from
alpha-cyclodextrin and perfluoroperhydrophenanthrene. A number of different
complexation techniques were employed and the products were characterized by Fourier
transform infrared spectroscopy, thermogravimetric analysis, and X-ray diffraction.
Following analysis, the most effective preparation technique was identified for application
as an oxygen carrier for tissue engineering.

Keywords: cyclodextrin, inclusion complex, perfluorocarbon

3.1 Introduction
Cyclodextrins are cyclic oligosaccharides with a unique toroidal shape which allows them
to accommodate a variety of guest molecules within their cavity, forming non-covalent
host-guest systems known as inclusion complexes. Cyclodextrins are natural and relatively
non-toxic materials, making them suitable for biological applications, they have a low
price, and are commercially available. 1 Perfluorocarbons are organic molecules where the
carbon network is surrounded entirely by fluorine atoms and they have the ability to
dissolve large quantities of non-polar gases such as oxygen. Perfluorocarbons have been
extensively explored as oxygen carriers to enhance the delivery of oxygen to cells in
scaffold-guided tissue engineering applications. However, previous approaches involving
PFCs have focused on fabricating PFC emulsions which lack stability and are not overall
user-friendly.2 Moreover, the high density of the emulsions causes them to settle in the
culture well or medium reservoir.3 This study explores the preparation and characterization
of a cyclodextrin inclusion complex with a perfluorocarbon as a novel oxygen carrier for
application in tissue engineering. Because inclusion of a guest molecule within the
cyclodextrin cavity can provide stabilization, it may serve to overcome some of the
shortcomings of PFC emulsions. Moreover, cyclodextrin inclusion complexes have been
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incorporated into 3D scaffolds via electrospinning;4-6 this immobilization of the CD:IC
within the scaffold would impart enhanced oxygen delivery throughout the construct, and
delay or prevent settling of the PCFs in the culture well or medium reservoir.

Table 3-1: Comparison of the dimensions of potential cyclodextrin host molecules to
those of perfluorocarbon guest molecules. Sizes of guest molecules are approximated
from a computer simulation.
Cyclodextrin
α-CD
β-CD
γ-CD
Guest Molecule
PFD
PFP

Cavity Diameter (Å)
4.7-5.3
6.0-6.5
7.5-8.3
Diameter (Å)
3
5

Cavity Height (Å)
7.9
7.9
7.9
Height (Å)
6-7
11-12

The formation of a cyclodextrin inclusion complex depends largely on the agreement
between the dimensions of the cyclodextrin cavity and the guest molecule. Table 3-1
shows the dimensions of the cyclodextrins and the guest molecules considered in this study.
Perfluorodecalin (PFD) and perfluoroperhydrophenanthrene (PFP) were the PFC guest
molecules considered in this study and their molecular structures are shown in Figure 3-1.
PFD dissolves a high level of oxygen (100 mL of PFD dissolves roughly 40 mL of O 2 at
37 °C) and has a longer tissue retention time than the most widely used perflubron which
suggests potential for clinical application. 7 Furthermore, the feasibility of PFD as an
oxygen carrier has been studied previously in our lab with promising results. 8, 9 PFP, on
the other hand, has been used as a perfluorinated, high molecular weight high boiling point
oil additive to help prevent instability and retard phase separation in emulsions of PFD. 10,
11

From Table 3-1, it is clear that the best match of host and guest dimensions is between

α-CD and PFP, with the 5 Å diameter PFC able to fit snugly inside the α-CD cavity. For
this reason, PFP and α-CD were the components used to prepare the inclusion complex in
this study. In fact, consistent with the internal cavity diameter, Druliner and Wasserman 12
reported that among a group of perfluoroalkanes studied, PFP was the only case in which
any evidence of inclusion complex formation with α-CD was found. It should be noticed
that considering that the depth of the CD cavity is roughly 8 Å, it is possible that two CD
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rings can be threaded onto a single chain of the PFP. 1 Therefore, both 1:1 and 2:1 αCD:PFP molar ratios were explored in the methodology.

Complexes can be formed via numerous techniques, and the selection is dependent on the
characteristic properties of the specific guest molecule and the equipment available. 13
Three complexation techniques were tested for optimal results in the preparation of the
PFP/α-CD complexes: co-precipitation, paste mixing, and dry mixing, as reviewed in
Section 2.4.2. When the cyclodextrin covers the guest molecule, either partially or entirely,
it provides stabilization and protection, and alters many of the physiochemical properties
of the guest.5,

14

These physiochemical changes are the basis for the characterization

techniques used to confirm that the guest is indeed contained within the cyclodextrin
cavity.

Figure 3-1: Molecular structure of perfluorodecalin (PFD, left) and
perfluoroperhydrophenanthrene (PFP, right)

3.2 Materials
Perfluoroperhydrophenanthrene (C14F24) was obtained as a mixture of isomers (83 %
purity) from Alfa Aesar (Ward Hill, MA). Perfluorodecalin (C10F18) was obtained as a
mixture of cis and trans isomers (99.9 % purity) from Sigma Aldrich (Milwaukee, WI)
Alpha-cyclodextrin (α-CD, 100 % purity) and beta-cyclodextrin (β-CD, 10.8 % moisture)
were obtained commercially from Alfa Aesar. Solvents were purchased from Caledon Labs
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(Georgetown, ON). All other chemicals were purchased from Sigma Aldrich. Unless noted
otherwise, all chemicals were used as received without any further modification.

3.3 Methods
Preliminary Studies
Initial complexation studies were carried out using PFD as the guest molecule with both αCD and β-CD as hosts. The co-precipitation technique was carried out at both a 1:1 and 2:1
CD:PFD molar ratio.

Alpha- or beta-cyclodextrin was added to de-ionized (d.i.) water to create a saturated
aqueous solution. Weighed amounts of PFD were added to the α-CD solution at a ratio of
1:1 or 2:1 CD to PFC. The solution was stirred continuously and vigorously (1000 rpm) at
room temperature (RT) in a sealed vial. After 72 hours of mixing, the solvent (water) was
evaporated over 2-3 days in an open system in order to obtain a solid product. The solid
product was dried and stored in a desiccator with potassium hydroxide used as a desiccant.

Preparation

of

Cyclodextrin

Inclusion

Complexes

with

Perfluoroperhydrophenanthrene
Throughout this chapter, α-CD is referred to as the “host” and PFP is referred to as the
“guest”. Three complexation techniques were studied to obtain an inclusion complex
between α-CD and PFP: co-precipitation, paste mixing, and dry mixing. All complexation
techniques were carried out at both 1:1 and 2:1 molar ratios of α-CD to PFP (host to guest).
Following complexation the product was not washed because the washing process is often
detrimental to the complex.

3.3.2.1 Co-precipitation
The solid α-CD/PFP complexes were prepared using a co-precipitation method modified
from a previously reported method also utilizing a PFC. 15 Heating can be used to increase
the amount of CD dissolved, thus increasing the probability of complexation. Therefore, in
addition to RT, co-precipitation was carried out at the mild temperature of 40 °C, as most
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complexes begin to decompose at 50-60 °C.16 The amount of solvent required was
minimized, to prevent the guest molecule from becoming too dilute that it does not come
in contact with the CD in sufficient amounts to facilitate complexation. Moreover, because
the guest molecule is a high molecular weight fluorocarbon, it may preferentially associate
with itself as opposed to interact with the CD, so a vigorous amount of stirring was utilized
in order to disperse and separate the guest molecules from each other. 16

Alpha-cyclodextrin was added to d.i. water to create a saturated aqueous solution. Weighed
amounts of PFP were added to the α-CD solution at a ratio of 1:1 or 2:1 α-CD to PFP. The
solution was stirred continuously at 1000 rpm at either RT or 40 °C in a sealed vial. After
72 hours of stirring, the solvent (water) was evaporated over 2-3 days in an open system at
RT in order to obtain a solid product. The solid product was dried and stored in a desiccator
with potassium hydroxide used as a desiccant.

3.3.2.2 Paste Mixing
Weighed amounts of α-CD and a minimal amount of d.i. water were combined to form a
paste. Weighed amounts of PFP were added to the α-CD paste at a 1:1 or 2:1 α-CD to PFP
molar ratio. The paste was thoroughly mixed using a ceramic mortar and pestle for ten
minutes. The product was collected in a glass vial, dried and stored in a desiccator with
potassium hydroxide used as a desiccant.

3.3.2.3 Dry Mixing
Weighed amounts of α-CD and PFP were combined at a 1:1 or 2:1 α-CD to PFP molar
ratio. The dry mixture was thoroughly mixed with a ceramic mortar and pestle for ten
minutes. The solid product was collected and stored in a desiccator with potassium
hydroxide used as a desiccant.

Fourier Transform Infrared Spectroscopy
The products obtained in the preliminary studies were characterized by Fourier transform
infrared (FTIR) spectrometry using a Bruker Vector 22 (Bruker Optics, Billerica, MA)
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equipped with a MIRacle Attenuated Total Reflectance (ATR) diamond crystal plate
sample cell (PIKE Technologies, Madison, WI). In the follow-up studies, FTIR
characterization of the α-CD/PFP complexes was carried out on a Bruker Tensor 27
spectrometer equipped with an ATR attachment using a ZnSe crystal.

In all cases, the samples were run as fine powders or a liquid (in the case of PFP) for 32
scans with a resolution of 4 cm-1 over the scan range 600 to 4000 cm-1. All spectra were
collected and processed with the OPUS software version 6.5. Absorption frequencies are
reported in wavenumbers (cm-1).

Thermogravimetric Analysis
Thermogravimetric analysis (TGA) was performed using an SDT Q600 Thermal Analyzer
(TA Instruments, USA). Experiments were performed under nitrogen at a heating rate of
10 °C/min up to 600 °C. The real time weight loss as a function of temperature was
recorded during the experiment using the Universal Analysis 2000 data acquisition system.

X-ray Diffraction
X-ray diffraction (XRD) spectra were collected with a Rigaku Ultima IV X-ray Diffraction
Generator (Rigaku, Japan). The patterns were measured in the continuous mode, applying
a CuΚα X-ray source at a range of 2θ = 2 – 60° with a scan rate of 2 °/min. The applied
voltage and current were set to 40 kV and 40 mA, respectively.

3.4 Results
Preliminary Studies
Preliminary studies were carried out with PFD as the guest molecule for inclusion
complexation with cyclodextrin. PFD was readily available and had been used previously
in our lab as an oxygen carrier with promising results. 8,

9

The products of the co-

precipitation complexation technique between both α- and β-CD and PFD were analyzed
with FTIR spectroscopy. The FTIR spectra are shown in Figure 3-2 and Figure 3-3 for αCD and β-CD, respectively. The FTIR spectra of the products are compared to those of the
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native CDs and as-received PFD. Peaks characteristic of the PFD guest are not evident in
the FTIR spectra of the products. In fact, the spectra of the products are virtually identical
to those of the respective parent CDs. Therefore, there is a lack of evidence of complexation
with PFD in the FTIR spectra for either α-CD or β-CD. It is likely that an inclusion complex
did not form between these specific host and guest molecules because of an unsuitable
match between the dimensions of PFD and the CD cavity. The diameter of PFD is much
smaller than the width of both the α- and β-CD cavity. Molecules of a very small size do
not form stable complexes with cyclodextrins as they slip out of the cavity. As
demonstrated in Table 3-1, the best match of host and guest dimensions is between α-CD
and PFP. As such, the focus of further studies was complexation between α-CD and PFP.
Furthermore, the number of complexation techniques explored was expanded in order to
test for optimal results of complexation between α-CD and PFP.

Furthermore, the complexes were initially dried in a vacuum oven at RT. However, it
became apparent that this procedure likely compromised the product because most
complexes start to decompose at 50-60°C.16 Thus, the procedure was altered and the
complexes were dried in a desiccator as suggested in the literature for extremely delicate
complexes in order to minimize the loss of the guest.16
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Figure 3-2: FTIR spectra of (i) unmodified α-CD, products of RT co-precipitation at
a (ii) 2:1 and (iii) 1:1 molar ratio, and (iv) as-received PFD
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Figure 3-3: FTIR spectra of (i) unmodified β-CD, products of RT co-precipitation at
a (ii) 2:1 and (iii) 1:1 molar ratio, and (iv) as-received PFD
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Fourier Transform Infrared Spectroscopy
FTIR spectroscopy was carried out on the products obtained from each of the complexation
techniques: co-precipitation, paste mixing, and dry mixing. FTIR spectroscopic techniques
are not generally suitable for conclusively confirming the formation of an inclusion
complex because there are only slight shifts and changes upon complexation. 17 There are
interferences in the spectra from the cyclodextrin, and some of the changes are very subtle,
requiring careful interpretation of the spectrum. 13 Moreover, if the fraction of the guest
molecule included within the cyclodextrin cavity is less than 25 %, the bands which could
be assigned to the guest molecule can be masked by the bands of the cyclodextrin and the
water of crystallization.14, 17, 18 Nevertheless, changes in the fingerprint region (below 1300
cm-1) can confirm that the products are different from each parent molecule as they possess
new spectroscopic signals. Thus, FTIR was used in this study as an initial characterization
technique because it is both inexpensive and readily available. The slight changes in the
spectra of the products were used to identify the complexation techniques that were most
effective.

The various complexation techniques utilized in this study were carried out at both 1:1 and
2:1 host to guest (α-CD:PFP) molar ratios; the FTIR spectra for these products are shown
in Figure 3-4 and Figure 3-5, respectively. The FTIR spectra of the products are compared
to those of the native α-CD, as-received PFP, and 1:1 or 2:1 physical mixtures of the two
parent molecules. The spectrum for the unmodified α-CD shows peaks at 1024 and 1076
cm-1 corresponding to coupled C-C/C-O stretching vibrations, and at 1153 cm -1
corresponding to the anti-symmetric stretching vibration of the C-O-C glucosidic bridge,
in agreement with the literature.19, 20 Furthermore, a broad band at roughly 3300 cm-1 is
attributed to the symmetric and anti-symmetric OH stretching, and a peak at roughly 2900
cm-1 is attributed to C-H vibrations.21,

22

When complex formation occurs, there is

frequently a slight shift in the hydroxyl band which is usually ascribed to hydrogen bonding
or other intermolecular interactions between the CD and guest molecule.23, 24
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Figure 3-4: FTIR spectra of (i) unmodified α-CD, (ii) physical mixture of α-CD and
PFP at a 1:1 molar ratio, inclusion complexes formed at a 1:1 (CD:PFP) molar ratio
via (iii) dry mixing, (iv) paste mixing, (v) co-precipitation at 40°C, (vi) co-precipitation
at RT(vii) and as-received PFP
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Figure 3-5: FTIR spectra of (i) unmodified α-CD, (ii) physical mixture of α-CD and
PFP at a 2:1 molar ratio, inclusion complexes formed at a 2:1 (CD:PFP) molar ratio
via (iii) dry mixing, (iv) paste mixing, (v) co-precipitation at 40°C, (vi) co-precipitation
at RT(vii) and as-received PFP
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Table 3-2: Characteristic peaks (cm-1) of PFP and the corresponding peaks observed
in the products of various complexation techniques at both 1:1 and 2:1 molar ratios
of α-CD and PFP. A double dash indicates that a peak was not observed at that
wavenumber.
Peak PFP
A
B
C
D
E
F
G

1323
1207
1188
1101
1018
970
910

Peak PFP
A
B
C
D
E
F
G

1323
1207
1188
1101
1018
970
910

1:1
Physical
Mixture
1323
1209
1188
1099
1018
970
910
2:1
Physical
Mixture
1323
1209
1190
1099
1018
970
910

1:1 Coprecipitation RT

1:1 Coprecipitation 40

1:1 Paste
Mixing

1:1 Dry
Mixing

1329
--1094
--905

1323
1209
1188
1101
1018
970
910

1325
1211
1192
1094
1020
972
910

1325
1211
1190
1094
1018
972
910

2:1 Coprecipitation RT

2:1 Coprecipitation 40

2:1 Paste
Mixing

2:1 Dry
Mixing

1329
---1022
-904

1331
--1094
1024
-905

1325
1211
1192
1094
1020
972
912

1325
1211
1192
1093
1020
972
910

Peaks characteristic of the PFC guest are evident in the spectra of the products (Figure 3-4
and Figure 3-5). Unequivocal assignment of the FTIR bands of PFP is beyond the scope
of the present work. Nonetheless, a number of these characteristic peaks were selected such
that they did not overlap with strong absorption bands for the α-CD and are denoted by the
letters A-G. The wavenumbers at which these peaks occur shifts slightly upon
complexation; the shifts observed in this study for the selected peaks are tabulated in Table
3-2. A more thorough and quantitative characterization of the complexes was carried out
by further analyzing the absorbance at these characteristic peaks. First, the absorbance
value at each characteristic peak was divided by the absorbance values at the equivalent
peak in the corresponding physical mixture, serving as an external standard. Secondly, the
resulting values were divided by their average, acting as an internal standard. Finally, the
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standard deviation of these normalized values was calculated and they are presented in
Table 3-3. The standard deviation quantitatively demonstrates the difference between the
peaks observed in the product and those observed in the physical mixture. Simply put, a
larger standard deviation signifies a larger chemical shift (complexation), relative to the
physical mixture.

Table 3-3: Absorbance values at peaks characteristic of PFP, normalized to physical
mixture (external standard) and concentration (internal standard) for products
prepared via various complexation techniques at both a 1:1 and 2:1 ratio of α-CD and
PFP
Peak
A
B
C
D
E
F
G
St. Dev.
Peak
A
B
C
D
E
F
G
St. Dev.

1:1 Coprecipitation RT
0.96
--1.55
--0.50
0.53

1:1 Coprecipitation 40
0.95
1.02
1.03
1.09
1.01
0.93
0.98
0.05

1:1 Paste
Mixing
1.29
0.80
0.70
1.32
1.38
0.85
0.67
0.31

1:1 Dry
Mixing
1.23
1.03
0.92
1.08
1.17
0.84
0.74
0.18

2:1 Coprecipitation RT
1.09
---1.22
-0.69
0.27

2:1 Coprecipitation 40
0.91
--1.41
1.20
-0.49
0.40

2:1 Paste
Mixing
1.15
0.57
0.54
1.51
1.54
0.91
0.78
0.41

2:1 Dry
Mixing
1.11
0.79
0.72
1.34
1.15
0.98
0.92
0.22

Inclusion complex formation is characterized by weak, non-covalent interactions between
the host and guest molecules. In addition to van der Waals forces, hydrophobic interactions
are predicted to be involved in the inclusion of the PFP molecule within the α-CD cavity.
During the co-precipitation technique, there are strong repulsions between the water
molecules and the hydrophobic PFC. PFP can avoid contact with the water molecules by
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entering the CD cavity and forming an inclusion complex. In addition, this results in the
expulsion of enthalpy-rich, energetically unfavoured water molecules present in the
slightly apolar cyclodextrin cavity. The expelled water molecules are taken up by the bulk
solution where they can form more hydrogen bonds than when contained in the
cyclodextrin cavity, and therefore gain degrees of freedom and contribute to the stability
of the complex owing to the increase in entropy.17, 18 In a 1:1 conformation the guest would
partially stick out of the α-CD cavity. Since the main driving force of this complexation is
the minimization of the contact between the PFC and the aqueous environment, it can
reasonably be expected that each PFP molecule would prefer to be totally covered by CDs.
Consequently a 2:1 α-CD:PFP complex is more likely. However, it is evident from the
FTIR spectra of the products obtained via the co-precipitation complexation technique at
both 1:1 and 2:1 at RT, as well as at 2:1 and 40 °C, that salient peaks characteristic of PFP
at 1207 and 1188 cm-1 (B and C, respectively in Figure 3-4 and Figure 3-5) were not
observed. In fact, these spectra are almost identical to that of the un-modified α-CD and it
can be concluded that these techniques are not effective in preparing an inclusion complex
from these specific host and guest molecules. In contrast, the product prepared via 1:1 coprecipitation at 40 °C does show the peaks characteristic of the PFP guest. However, when
compared to the corresponding physical mixture the standard deviation of the normalized
absorbance values is exceptionally low (Table 3-3). This demonstrates that the product
from this technique is actually only a physical mixture of the two parent components and
inclusion of the PFP within the α-CD cavity did not occur.

Overall, the FTIR spectra of the products prepared via both the dry and paste mixing
techniques indicate successful inclusion complex formation as the characteristic peaks of
PFP, A-G in Figure 3-4 and Figure 3-5, are visible. In fact, it is evident that these
characteristic peaks have shifted slightly (Table 3-2). For example, the characteristic bands
of PFP at 1207 and 1188 cm-1 shifted to 1211 and 1192 cm-1, respectively for both the 2:1
paste and dry mixing techniques. These peaks are also different than those observed in the
2:1 physical mixture, at 1209 and 1190 cm -1, respectively. This suggests that host-guest
interactions were formed in the product and is in agreement with the literature where
similar shifts were reported.1, 15, 25 Further evidence of the effectiveness of the mixing
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techniques is that the characteristic peaks were suppressed when compared to both PFP
and the physical mixture. The attenuation of the absorption bands of guest molecules is
typically observed for CD:IC systems because the inclusion of the guest molecules in the
CD cavity hinders their molecular vibrations, and therefore the intensity of their absorption
bands is diminished.26 Furthermore, the standard deviations of the absorbance values
obtained for these products indicate significant differences from their corresponding
physical mixtures (Table 3-3). It is likely that the mixing techniques were more successful
than co-precipitation in preparing an inclusion complex with this specific guest due to its
liquid form. The PFP may not have associated with the CD in solution in an amount
sufficient to facilitate complexation for two reasons: it is possible that the PFP was too
dilute in the aqueous solvent, and because PFP is a high molecular weight compound, it
may preferentially associate with itself even with vigorous stirring. However, one of the
limitations of the mixing techniques is the inability to guarantee homogeneous mixing;
thus, the product may be a mixture of host, guest, and complex. In fact, the complexes
prepared via the mixing technique at a 1:1 molar ratio show a larger hydroxyl vibrational
band (roughly 3300 cm-1), potentially due to an amount of uncomplexed CD remaining in
the product. Although this could be remedied by washing the product, there is a risk of
destroying the complex or decreasing the product yield.
The complexes prepared at a 2:1 molar ratio of the α-CD host to the PFP guest appeared to
be the most successful overall. This corresponds with the α-CD cavity height being smaller
than that of the PFP so that in order for the PFP to be fully covered, two α-CD molecules
must be threaded onto one PFP molecule. Further characterization techniques were only
carried out on the samples prepared at a 2:1 molar ratio.

Thermogravimetric Analysis
TGA was carried out on the products of the co-precipitation, paste mixing, and dry mixing
complexation techniques carried out at a 2:1 molar ratio (α-CD:PFP) for further
confirmation of the formation of an inclusion complex. Thermal characterization
techniques involve analyzing the broadening, shifting, and disappearance of existing peaks,
as well as the appearance of new peaks, when compared to the parent molecules and/or the
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physical mixture of the parent molecules. The thermograms for the parent molecules, αCD and PFP, their 2:1 physical mixture, and complexes prepared from co-precipitation (at
RT), paste mixing, and dry mixing are shown in Figure 3-6. The TGA data is presented as
weight percent, and both derivative weight and derivative heat flow (with respect to
temperature) versus temperature.
The thermogram for α-CD shows two mass losses centered at 60 and 90 °C, corresponding
to a loss of absorbed water and water of crystallization, and a third at 320 °C corresponding
to its decomposition.27 PFP, with a reported boiling point of 214-216 °C,28 shows a mass
loss centered at 165 °C, corresponding to its complete vaporization. The difference with
the literature data may be due different isomeric composition or the relatively low purity
of the PFP molecule used in this study. The thermogram for the 2:1 physical mixture of αCD and PFP appears to be almost identical to that obtained for pure α-CD. This is
potentially due to incomplete mixing of the parent molecules with the result that the
fraction used for TGA analysis did not contain any PFP. It was not possible to remedy this
by more thoroughly mixing the components as this would, in effect, be carrying out the dry
mixing complexation technique.

The thermograms for the products prepared by different complexation techniques all show
two mass losses which occur at approximately 100 and 320 °C. The latter peak clearly
corresponds to the degradation of α-CD. The loss of PFP overlaps with the loss of water at
100 °C, and it was therefore difficult to elucidate differences in the thermograms by looking
solely at weight loss and derivative weight. Comparing the derivative heat flow for the
product prepared via co-precipitation (at RT) to that for α-CD, some differences are
observed; however, the same basic shape of the thermogram of CD is maintained. For
example, there are still two peaks around 100 °C, and although they have shifted slightly,
the shifts are not sufficient to confirm complex formation. These results are in agreement
with the FTIR results discussed previously (Section 3.4.2).

The derivative heat flow (with respect to temperature) for the product prepared via dry
mixing shows a very similar pattern to that of α-CD around 100 °C, indicating a large mass
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loss at this temperature corresponds to the release of water. There are noticeable
differences, however, starting at 300 °C when the α-CD begins to decompose. This
provides evidence that some PFP was in fact included within the CD cavity, such that it
was thermally stabilized and did not evaporate until the CD began to decompose, in
agreement with results reported in the literature. 29 The product prepared via paste mixing,
on the other hand, shows a different derivative heat flow at both 100 and 320 °C. This
indicates that this technique was more effective, with more PFP included within the cavity.
Around 100 °C, there is only one endothermic peak, indicating that there was some degree
of displacement of water molecules from the host CD cavity, which corresponds to the
inclusion of PFP within that cavity.26

If PFP molecules escape from the α-CD cavities at temperatures below 300 °C when α-CD
begins to decompose, the weight loss should correspond to the mass fraction of PFP in the
complexes. In the case that the CD:IC contains no water of crystallization, the calculated
mass fraction of PFP approaches 25 %. However, it is clear from the thermograms,
specifically those showing derivative heat flow, that there is some water remaining in the
complexes, and therefore the calculated mass fraction of PFP is overestimated. The amount
of water bound to the complex could likely be further decreased by using a more effective
drying technique, such as heat-drying, however, this could be detrimental to the complex.
The calculated mass loss below 123 °C for the complex prepared via paste mixing is less
than the calculated expected mass loss. Taking into consideration that the observed mass
loss also includes water loss, this is further evidence that some PFP was included within
the α-CD cavity and was not thermally altered until the temperature at which the α-CD
began to decompose. It is possible that some of the product of paste complexation is an
inclusion complex and some is simply a physical mixture of the parent molecules.
Increasing the mixing time for paste complexation could serve to reduce the amount of
uncomplexed α-CD in the product.
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Figure 3-6: TGA thermograms of unmodified α-CD and PFP, their 2:1 physical
mixture, and complexes prepared via co-precipitation (at RT), paste mixing, and
dry mixing at a 2:1 molar ratio
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Unfortunately, the main thermal event for PFP in the complexes was not increased as is the
case most reported in the literature for evidence supporting the formation of a stable
inclusion complex.15, 25, 30 Interaction of the guest with the cyclodextrin provides a higher
energy barrier to overcome for volatilization resulting in an increase in boiling temperature
of about 10 °C.13 On the other hand, the inclusion complexes prepared with volatile guests
often do not have substantially higher thermal decomposition temperatures. 26 In this case,
it was actually observed that the PFP in the products evaporated at a lower temperature
than the unmodified PFP. Although inclusion within the cyclodextrin cavity can provide
stability for the guest molecule, in this case the interactions with the CD cavity are weaker
than those formed in the bulk solution between the liquid PFP molecules. It is also possible
that the guest is not completely included within the cyclodextrin cavity, but rather is closed
in a void space of a lattice or aggregated to the outside of the cyclodextrin, forming a
microcrystalline or amorphous powder.14, 17, 31 This type of complex would have a much
lower stability than if the guest was included entirely within the cyclodextrin cavity.
Nevertheless, it was observed that some of the PFP was not removed until the CD began
to decompose which has also been reported in the literature as evidence supporting the
formation of an inclusion complex.5, 29

Overall, thermal characterization using TGA did not prove to be an effective technique for
confirming complex formation between the host and guest molecules used in this study.
This was mainly due to the similarity of the guest vaporization temperature to that for
water. Nonetheless, it was possible to further ascertain the effectiveness of the different
complexation techniques, specifically providing the opportunity to further distinguish the
differences between the paste and dry mixing complexation techniques, which showed
similar efficacy when analyzed using FTIR. Overall, the TGA data suggests that the paste
mixing technique was the most effective whereas co-precipitation (at RT) was the least
effective, which is in agreement with the data obtained from FTIR characterization. The
paste mixing technique is likely more effective due to the small amount of water utilized
in this preparation technique which acts as a driving force for the PFP molecule to enter
the hydrophobic CD cavity in order to reduce contact with the aqueous environment.
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X-ray Diffraction
After initial characterization with FTIR, it was determined that inclusion complex
formation occurred preferentially at a 2:1 α-CD:PFP molar ratio. XRD was carried out on
complexes prepared at this ratio using co-precipitation (at RT), paste mixing, and dry
mixing techniques. When an inclusion complex is formed with a solid substance as a guest,
a comparison has to be made between the diffractogram of the product and that of the
physical mixture of the two parent molecules. However, in the case of a liquid guest, as
with PFP, no comparison is necessary because liquids do not have diffraction patterns of
their own. Therefore, if the diffraction pattern of the product clearly differs from that of the
unmodified cyclodextrin, the difference indicates complex formation. Complex formation
leads to the sharpening and/or shifting of existing peaks, as well as the appearance of a few
new peaks.14, 18
CDs are crystalline and have crystal structures referred to as cage or channel type. 32 The
as-received CDs have a cage type packing structure characteristic of a random packing
arrangement. In cage type packing, the CDs are arranged in a herringbone pattern (Figure
3-7c) where both openings of each CD unit are closed by adjacent CD molecules. CDs take
this form when small molecules, such as water, are included in its cavity. In general, CD
molecules form the channel type arrangement when they are in an inclusion complex
conformation. In this arrangement the CDs are aligned and stacked on top of each other in
a head-to-head (Figure 3-7b) or head-to-tail fashion (Figure 3-7a), forming cylindrical
channels.5 Depending on the nature and dimension of the guest, a variety of conformations
can be adopted, from perfectly aligned to more or less displaced, possibly forming, in the
most favourable case, endless channels.33 The two salient peaks in X-ray diffractograms
most commonly reported as corresponding to the channel type packing structure for α-CD
are centered at 2θ ≈ 13° and 20°.19 These peaks have also been reported as 2θ ≈ 19.6° and
22.3°.19
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(a)

(b)

(c)

Figure 3-7: Possible cyclodextrin conformations (a) headto-tail channel structure (b) head-to-tail channel structure
(c) cage structure

XRD spectra for the host, α-CD, and products of the 2:1 co-precipitation (at RT), paste
mixing, and dry mixing complexation techniques are shown in Figure 3-8. Salient peaks
at 9.72°, 12.13°, 14.32°, and 21.67° previously reported as characteristic of cage-type
packing in α-CD were observed and are denoted in Figure 3-8 by an asterisk.

62

The diffractogram for the product obtained via co-precipitation (at RT) shows a spectrum
very different from that of the host α-CD. It can be seen that not only is there disappearance
of characteristic peaks from the parent spectra, there is both sharpening and shifting of
existing peaks. Furthermore, the peaks at 19.64° and 22.34° (A and B, respectively in
Figure 3-8) can be attributed to the α-CD adopting a channel structure due to the formation
of an inclusion complex.21, 34 It is possible that some of these changes can be attributed to
recrystallization of the α-CD from the aqueous solvent used in the co-precipitation
technique.

Dry Mixing

Intensity

Paste Mixing

A

B

Co-precipitation

*
*
*

*
α-CD

8

14

20

26

32

2θ (°)

Figure 3-8: XRD comparison of CD:ICs prepared from α-CD and PFP via different
complexation techniques at a 2:1 host:guest ratio and that of the unmodified α-CD
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The diffractogram for the product obtained via paste mixing shows a very similar spectrum
to that of α-CD but with increased intensity. This can be attributed to a large amount of
uncomplexed CD remaining in the product, possibly owing to the contribution of 1:1
complexes in the product, resulting in an overall stoichiometric ratio less than 2:1. 22 The
XRD results for the product obtained via dry mixing, on the other hand, show a severely
diminished structure when compared to the host diffractogram. Specifically, the peaks
previously identified as being characteristic of a cage type structure in the host have either
disappeared, in the case of the peak at 9.72°, or noticeably dwarfed, especially with the
peak at 21.67°.

Overall, because the diffraction patterns do not correspond exactly to those of the
unmodified parent molecule, a true inclusion complex may exist. Products obtained by the
three different complexation techniques all show unique features when compared to the
diffractogram for α-CD.

3.5 Conclusion
Taken together, the results of the FTIR, TGA, and XRD characterization techniques
confirm that inclusion complexation did in fact occur between the selected host and guest
molecules, α-CD and PFP respectively. Following characterization with FTIR, it was
possible to narrow down the complexation techniques and conditions to those most
effective at yielding true complex formation. It was evident that a 2:1 molar ratio of the αCD host to PFP guest was preferred. This corresponds with the α-CD cavity height being
smaller than that of the PFP so that in order for the CD to be fully covered, two α-CD
molecules must be threaded onto one PFP molecule. From the FTIR spectra, it was also
apparent that the mixing techniques were more effective than co-precipitation. Peaks
characteristic of the PFP guest molecule were visible in the spectra for the mixing
techniques, and in fact the peaks were both shifted and suppressed when compared to the
FTIR spectra of the as-received PFP. These spectral features are evidence of host-guest
interactions and the cavity hindering the vibrations of the PFP, ultimately indicating
successful complex formation. Finally, a comparison of the standard deviations of
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normalized absorbance values at the characteristic peaks indicated that the products
prepared via the mixing technique were sufficiently different than the corresponding
physical mixtures.

TGA was subsequently carried out on the products of 2:1 co-precipitation (at RT), paste
mixing, and dry mixing. This characterization technique was difficult with the specific
guest molecule used in this study due to the similarity of its main thermal event to that of
water. Nevertheless, the differences in the derivative heat flow thermograms for the
products were sufficiently large compared to the thermogram of the unmodified α-CD to
demonstrate successful complexation. Overall, TGA analysis indicated that the paste
mixing technique was the most effective in preparing an inclusion complex in this study.

Finally, XRD was carried out on the products of the 2:1 co-precipitation (at RT), paste
mixing, and dry mixing. Differences in the diffractograms of the three products when
compared to that of the unmodified α-CD show differences including the disappearance,
sharpening, and shifting of existing peaks, as well as the occurrence of new peaks which
all suggest successful complexation. Further analysis indicated that the dry mixing
technique may be the most effective in preparing inclusion complexes between α-CD and
PFP. In summary, characterization of the products prepared via the different complexation
techniques utilized indicate that the mixing techniques were overall more effective than
co-precipitation. Although TGA provided evidence that paste mixing was the best
technique, characterization with XRD indicated that dry mixing may be more effective.
Nevertheless, the paste mixing technique was selected for preparing an inclusion complex
with α-CD and PFP due to its proven ability to produce the desired complex and the fact
that it allowed for simple handling and preparation of the complex.
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4 FABRICATION OF TISSUE ENGINEERED SCAFFOLDS
INCORPORATING CYCLODEXTRIN INCLUSION
COMPLEXES WITH
PERFLUOROPERHYDROPHENANTHRENE
Overview: This chapter discusses the incorporation of an inclusion complex from alphacyclodextrin and perfluoroperhydrophenanthrene in 3D tissue engineering constructs.
Scaffold fabrication was carried out via electrospinning and the inclusion complexes were
incorporated in both biodegradable (PCL) and stable (PCU) materials. Optimized
concentrations were identified and the effect of adding cyclodextrin explored. The resulting
fibrous mats were imaged with scanning electron microscopy and the surface content was
analyzed with X-ray photoelectron spectroscopy.

Keywords: 3D scaffold, electrospinning, tissue engineering, cyclodextrin, inclusion
complex, perfluorocarbons

4.1 Introduction
Tissue engineering involves the assembly of cells and their support structures for the repair
and regeneration of diseased or damaged tissues and organs as an alternative to current
therapies.1 One strategy of tissue engineering involves seeding cells onto a porous 3D
scaffold that supports in vitro tissue formation and maturation. One of the major factors
hindering the success of scaffold-guided tissue engineering is the inability to deliver
sufficient oxygen to the growing constructs. A number of strategies to improve oxygen
delivery have focused on the development of PFC emulsions. Although PFC emulsions
show excellent oxygen carrying capacity, they lack stability causing overall userunfriendliness and they have a high density causing them to settle in the culture well or
medium reservoir.2,

3

Another approach for improving oxygen delivery involves

embedding oxygen generating compounds, such as calcium peroxide 4 or sodium
percarbonate5 which decompose in water to produce oxygen, directly into the tissue
engineering scaffold. This approach has the advantage of providing oxygen throughout the
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construct, notably in the center where it is difficult to reach by diffusion alone, but it is
restricted because the oxygen generating compound is eventually depleted. Tissue
engineering scaffolds incorporating fluorinated porous zeolite particles provide an
alternative to this approach whereby the embedded compound does not generate oxygen
but enhances its delivery using the principles of oxygen solubility in perfluorocarbons. 6
Cyclodextrin inclusion complexes with perfluorocarbons have been prepared previously
for application as novel oxygen carriers. Because inclusion of a guest molecule within the
cyclodextrin cavity can provide stabilization, it may serve to overcome some of the
shortcomings of PFC emulsions. The goal of this study was to incorporate α-CD/PFP
inclusion complexes into 3D fibrous scaffolds. Embedding the CD/PFC complexes in the
scaffold would impart enhanced oxygen delivery throughout the construct, and delay or
prevent settling of the PCFs in the culture well or medium reservoir.

One of the most commonly utilized methods for scaffold fabrication is electrospinning.
Electrospinning is a versatile technique that enables the production of multi-functional
fibers in the nano- to micrometer range from a wide variety of materials and it is generally
a relatively simple, versatile, and cost-effective method. Because electrospinning allows
for the fabrication of scaffolds that closely mimic the scale and fibrous nature of the native
ECM, electrospinning was selected as the scaffold fabrication technique for this study. It
has been demonstrated that cyclodextrin inclusion complexes can be incorporated into
three-dimensional scaffolds via electrospinning.7-9 In fact, cyclodextrin has been shown to
positively affect the electrospinning of polymer solutions. The addition of CD increases
the conductivity of the polymer solution, allowing for successful electrospinning of beadfree fibers from lower polymer concentrations.10, 11 This is because the polymer solution is
subjected to higher stretching under the high electric field. 12 Moreover, it was reported that
preparation of a homogenous film from polymer/cyclodextrin solutions via other
fabrication techniques, such as spin coating or solvent casting methods, failed because the
CD molecules phase separated and formed crystal aggregates either immediately or upon
solvent evaporation.9, 12
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Depending on the intended application, scaffolds may be designed to be biodegradable so
that only the neo-tissue will remain after a given period of culture time or following
implantation, or they may be biostable such that a composite tissue that provides long-term
support could be fabricated.13-16 In the case of biodegradable scaffolds, cells will remodel
the scaffold with their own ECM proteins creating the intended tissue without
compromising tissue structural integrity. This, however, requires strict coordination of the
scaffold biodegradation rate with the biosynthetic rate and is one of the major obstacles in
the field today. In addition, a scaffold must have several required characteristics:
biocompatibility, appropriate mechanical strength and compliance, optimal porosity for
cell seeding, in vitro nutrient and oxygen transport, and the ability to bind to cells and
release growth factors when needed. PCU and PCL were selected as polymer materials
because they have previously been utilized as polymers for scaffold fabrication in our lab
and have been shown to have acceptable cell compatibility.17, 18 These polymer materials
present the opportunity for a proof of concept study showing that the CD/PFC inclusion
complex can be incorporated in both biostable (PCU) and biodegradable (PCL) tissue
engineering scaffolds.

4.2 Materials
Perfluoroperhydrophenanthrene (PFP, mixture of isomers, 83 % purity) and alphacyclodextrin (α-CD, 100 % purity) were obtained commercially from Alfa Aesar (Ward
Hill, MA). Medical grade poly(carbonate urethane) (PCU) (Bionate® 55D) was obtained
from DSM Biomedical (Berkeley, CA). Polycaprolactone (PCL), M n 70,000-90,000, was
purchased from Sigma Aldrich (Milwaukee, WI). Solvents were purchased from Caledon
Labs (Georgetown, ON). All other chemicals were purchased from Sigma Aldrich. Unless
noted otherwise, all chemicals were used as received without any further purification.

4.3 Methods
Preparation of Inclusion Complex
Weighed amounts of α-CD and a minimal amount of d.i. water were combined to form a
paste. Weighed amounts of PFP were added to the α-CD paste at a 2:1 α-CD to PFP molar
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ratio. The paste was thoroughly mixed using a ceramic mortar and pestle for ten minutes.
The product was collected in a glass vial, dried and stored in a desiccator with potassium
hydroxide as a desiccant. The products were analyzed with FTIR as discussed previously
(Section 3.3.3) to ensure successful complexation consistent with previous results (Section
3.4.2)

Fabrication of 3D Scaffolds
4.3.2.1 Electrospinning of Poly(carbonate urethane)
The polymer solution was prepared by varying concentrations of PCU in
N,N-dimethylformamide (DMF), and also varying the amount of CD:IC added. The
concentration of PCU ranged from 5-10 % (v/v) with respect to the solvent, and the
concentration of CD:IC ranged from 5-60 % (w/w) with respect to PCU. First, the PCU
was added to the corresponding amount of DMF and stirred until it was fully dissolved.
Then the corresponding amount of CD:IC was added and stirred until it was fully dispersed
in the polymer solution.
The electrospinning conditions used were based on those previously optimized in our lab. 17
The viscous polymer solution was transferred to a 0.5 mL glass syringe equipped with a
22 gauge stainless steel needle. The syringe was fixed horizontally on a syringe pump
(KD101, KD Scientific, USA) which maintained the flow rate at 0.1 mL/h and was
connected to a high voltage supply (ES30P, Gamma High Voltage, USA) which applied a
voltage of 15 kV. The fibers were collected on a grounded stationary metal collector
covered in aluminum foil, 8 cm from the needle tip. Following electrospinning, the
scaffolds were removed from the electrospinning assembly and the solvent was allowed to
evaporate in the fume hood.

4.3.2.2 Electrospinning of Polycaprolactone
The electrospinning of PCL was based on conditions obtained from literature, where a
cyclodextrin/naproxen inclusion complex was incorporated into electrospun PCL fibers.7
The polymer solution was prepared in a co-solvent mixture at a ratio of 3:1 or 1:1 DMF to
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dichloromethane (DCM). The concentration of PCL ranged from 5-10 % (v/v) with respect
to the total amount of solvent, and the concentration of CD:IC ranged from 15-50 % (w/w)
with respect to PCL. First, the PCL was added to the corresponding amount of DMF and
DCM solvents and stirred until it was fully dissolved. Then the corresponding amount of
CD:IC was added, with stirring and vortexing used in order to fully disperse the CD:IC in
the polymer solution.

The viscous polymer solution was then transferred to a 0.5 mL glass syringe equipped with
an 18, 20, or 22 gauge stainless steel needle. The syringe was fixed horizontally on a
syringe pump (KD101, KD Scientific, USA) which maintained the flow rate at 0.1 mL/h
and connected to a high voltage supply (ES30P, Gamma High Voltage, USA) which
applied a voltage of 15 kV. The fibers were collected on a grounded stationary metal
collector covered in aluminum foil, 8 or 10 cm from the needle tip. Following
electrospinning, the scaffolds were removed from the electrospinning assembly and the
solvent was allowed to evaporate in the fume hood.

Scanning Electron Microscopy
Fiber morphology of the electrospun fibrous mats was visualized using scanning electron
microscopy (SEM, 3400S, Hitachi, Ltd., Tokyo, Japan). The samples were mounted on
aluminum stubs with carbon tape and sputtered with osmium prior to analysis (courtesy of
the Nanofab facility, Filgen OPC80T, Japan). The stub was then placed in the SEM and
scanned at a working distance of 5 mm at a constant accelerating voltage of 5 kV. Images
were captured at various magnifications. The fiber diameters were measured using ImageJ
software (NIH, USA), analyzing a total of 100 fibers from three different fields of view at
10,000x magnification. Average fiber diameters were compared using the Student’s t-test
with significance assigned to p < 0.05.

X-Ray Photoelectron Spectroscopy
X-ray photoelectron spectroscopy (XPS) was carried out on the CD:IC and 3D scaffolds
using a Kratos Axis Ultra Spectrometer (Kratos Analytical Ltd. Manchester, UK) using a
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monochromatic Al Κα X-ray source (15 mA, 14 kV). The instrument work function was
calibrated to give a binding energy (BE) of 83.96 eV for the Au 4f7/2 line for metallic gold
and the spectrometer dispersion was adjusted to give a BE of 932.62 eV for the Cu 2p3/2
line of metallic copper. The Kratos charge neutralizer system was used on all samples,
which were analyzed to a depth of 5-7 nm, with detection limits ranging from 0.1 to 0.5
atomic percent depending on the element. Survey scans were carried out on an analysis
area of 300-700 µm at a pass energy of 160 eV. Spectra have been charge corrected to the
main line of the carbon 1s spectrum (adventitious carbon) set to 284.8 eV. Spectra were
analyzed using CasaXPS software version 2.3.14.

4.4 Results and Discussion
Three-dimensional Electrospun Fibrous Mats
Incorporating the inclusion complex prepared from α-CD and PFP into a 3D tissue
engineering scaffold affords the possibility of enhancing cell viability within the construct
due to the enhanced oxygen availability. In this study, electrospinning was used as a
scaffold fabrication technique because it allows for the fabrication of fibrous structures that
closely mimic the scale and fibrous nature of the native ECM, it is a relatively simple, costeffective, and versatile technique, and it has been reported that CD:ICs can be successfully
incorporated into scaffolds with this technique.

The method for preparing the electrospinning solution required optimization. Initially, the
solution components, PCU, CD:IC, and DMF, were added concurrently and stirred until
the polymer was fully dissolved and a homogeneous solution was produced. However, it
was observed that the PFP separated as liquid drops at the bottom of the mixture and was
displaced from the α-CD cavity, likely because the inclusion complex was destroyed during
solvation in DMF. The resolution to this problem was to first fully dissolve the polymer in
the solvent, and then add the CD:IC until it was thoroughly dispersed in the polymer
solution. As a result, no displaced PFP was observed. It is possible that this was due to the
non-ideality of the polymer solution, and that because the PCU is solvated in the DMF, the
DMF molecules are not able to displace the PFP from the CD cavity.
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Functionalized fibers were fabricated by electrospinning a PCU solution incorporating an
inclusion complex prepared from α-CD and PFP. The PCU concentration was varied,
testing the amounts 5, 7.5, 8, and 10 % (v/v) with respect to the DMF solvent. The amount
of CD:IC incorporated was also varied, from 5-60 % (w/w) with respect to PCU. The
concentration of CD:IC depended upon the specific PCU concentration being used, such
that when the CD:IC concentration was increased, the polymer concentration was
decreased. The sample nomenclature is based on the volume percentage of PCU and the
weight percentage of CD:IC used in the sample preparation. For example, 10PCU20CD:IC refers to an electrospun fibrous mat prepared from 10 % (v/v) PCU with respect
to the DMF solvent and 20 % (w/w) CD:IC with respect to PCU. Table 4-1 summarizes
the different PCU/CD:IC concentrations tested and the resulting fiber morphology.

Table 4-1: Concentrations of PCU/CD:IC
characteristics of the resulting fibers

electrospinning

solutions

and

% (v/v) PCU

% (w/w) CD:IC

Fiber Morphology

5
7.5
8
8
8
8
8
10
10
10
10

35
50
30
35
45
50
60
5
20
25
30

Heavily beaded nanofibers
Bead-free nanofibers
Bead-free nanofibers
Fused nanofibers
Not uniform, heavily beaded, nanofibers
Bead-free nanofibers
Not uniform, fused, beaded nanofibers
Thick, fused microfibers
Bead-free nanofibers
Bead-free nanofibers
Slightly beaded nanofibers

Interestingly, with the incorporation of cyclodextrin it was possible to produce uniform,
bead-free fibers from concentrations lower than 10 % (v/v) PCU. Our lab previously
reported that electrospinning concentrations lower than 10 % (v/v) PCU was not achievable
because the fibers were still wet when they reached the collector and fused with beading. 17
This ability to electrospin bead-free fibers from low polymer concentrations clearly
demonstrates the positive effect of cyclodextrin on electrospinning. The addition of CD
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increases the conductivity of the polymer solution, causing it to be subjected to greater
stretching under the high electric field. 10, 12, 11 Bead-free, uniform fibers were obtained at
both 7.5 and 8 % PCU with the incorporation of various amount of cyclodextrin (Table
4-1). However, when the PCU concentration was reduced to 5 %, vastly beaded fibers were
obtained (see Figure 4-1A) because there was not enough chain entanglement and
overlapping to create a stable jet.19

A

B

C

D

Figure 4-1: Representative SEM images of electrospun mats at 10,000x magnification
(A) 5 % (v/v) PCU, 35 % (w/w) CD:IC (B) 8 % (v/v) PCU, 60 % (w/w) CD:IC (C) 8
% (v/v) PCU, 50 % (w/w) CD:IC (D) 8 % (v/v) PCU, 50 % (w/w) α-CD
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Even though uniform, bead-free fibers were obtained at the initial tested concentrations of
10PCU-20CD:IC and 10PCU-25CD:IC, the ultimate objective of this work was to enhance
oxygen delivery to the cells eventually seeded onto these scaffolds; thus the goal was to
maximize the amount of CD:IC incorporated in the electrospun fibers. In order for the
solution to be electrospinnable and to produce uniform bead-free fibers, it was necessary
to decrease the polymer concentration as the amount of CD:IC incorporated was increased.
Figure 4-1B shows the non-uniformity of the fibers obtained from 8PCU-60CD:IC, where
the fiber diameter ranges considerably and various beads and other defects are present.
After the SEM images for all of the tested concentrations tested were analyzed, the optimal
concentration for the PCU/CD:IC solution was determined to be 8PCU-50CD:IC, shown
in Figure 4-1C. In addition to the fibers being bead-free, it can be seen that the fibers are
randomly oriented which is desirable for tissue engineering as it mimics the actual
physiological structure of the ECM and allows for cell infiltration, nutrient and waste
transport, and subsequent vascularization. Electrospinning was also carried out at the
optimized concentration with unmodified α-CD (8PCU-50CD), and the resulting fibers are
shown in Figure 4-1D. No notable differences were observed between the fibers
incorporating CD:IC compared to those with unmodified α-CD.

Because PCU is a biostable polymer, further electrospinning studies were carried out using
the biodegradable polymer PCL. In addition to its biodegradability, PCL was selected
because it is biocompatible, it is commonly used in the field of biomedical engineering,
and it is commercially available.18 The sample nomenclature is based on the volume
percentage of PCL and the weight percentage of CD:IC used in the sample preparation. For
example, 10PCL-20CD:IC refers to an electrospun fibrous mat prepared from 10 % (v/v)
PCL with respect to solvent and 20 % (w/w) CD:IC with respect to polymer. Table 4-2
summarizes the different concentrations tested and the resulting fiber morphology.
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Table 4-2: Concentrations of PCL/CD:IC electrospinning solutions, the
corresponding electrospinning conditions employed, and characteristics of the
resulting fibers
%
%
Solvent
Distance Needle
(v/v) (w/w) DMF:DCM
(cm)
Gauge
PCL CD:IC
Ratio
5

50

3:1

10

22

8

15

3:1

10

22

8

20

3:1

10

22

8

50

3:1

10

22

10

10

3:1

10

22

10

15

3:1

10

22

10

20

3:1

10

22

10

25

3:1

10

22

10

22

7.5

15

1:1
8

22

10

22

8

18

8

20

10

22

10

18

10

20

8

20

8

8

15

20

1:1

1:1

Fiber Morphology

Heavily beaded nanofibers
Uniform nanofibers with film
formation
Not uniform, nanofibers, film
formation
Not uniform, nanofibers, film
formation, CD precipitation
Not uniform, nanofibers, film
formation
Not uniform, mostly microfibers,
film formation
Not uniform, mostly microfibers,
film formation
Not uniform, mostly nanofibers,
film formation
Not uniform, mostly nanofibers,
some defects
Mostly uniform, mostly
nanofibers, few defects
Not uniform, mostly nanofibers,
some defects and beading
Mostly uniform, mostly
nanofibers, no defects
Uniform nanofibers, no defects
Not uniform, nanofibers, some
defects
Mostly uniform, mostly
microfibers, few defects
Mostly uniform, nanofibers, few
defects
Mostly uniform, nanofibers, few
defects
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As with the PCU-based solutions, the CD:IC had to be added to the solution after the PCL
was fully dissolved in the co-solvent system to prevent the displacement of the PFP from
the CD cavity. However, further difficulties were encountered as the polymer solutions
were highly viscous and the CD:IC could not be homogeneously dispersed. For this reason,
vortexing was added as a further step to the electrospinning solution preparation.

A

B

C

D

Figure 4-2: Representative SEM images of electrospun mats at 1,000x magnification
highlighting the film formation on the surface of the fibrous mats when a solvent ratio
of 3:1 DMF:DCM was used (A) 8 % (v/v) PCL, 15 % (w/w) CD:IC (B) 8 % (v/v) PCL,
20 % (w/w) CD:IC (C) 10 % (v/v) PCL, 10 % (w/w) CD:IC (D) 10 % (v/v) PCL, 20
% (w/w) CD:IC
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1,000 x

2,500 x

10,000 x

A

B

C

Figure 4-3: Representative SEM images of electrospun mats at multiple
magnifications (A) 7.5 % (v/v) PCL, 15 % CD:IC in 1:1 DMF:DCM (B) 8 %
(v/v) PCL, 15 % CD:IC in 1:1 DMF:DCM (C) 8 % (v/v) PCL, 20 % (w/w) CD:IC
in 1:1 DMF:DCM
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Following the conditions used by Canbolat et al., the PCL electrospinning solutions were
initially prepared with a co-solvent system of 3:1 (v/v) DMF:DCM, using a 22 gauge
needle and a distance of 10 cm between the needle tip and collector. 7 Even after
significantly varying the concentrations of both PCL and CD:IC, a film was observed on
the surface of the fibrous mat at the macro scale, as can be seen in Figure 4-2. Then, the
ratio of solvents was altered to 1:1 DMF:DCM, and the result was drastically reduced film
formation (Figure 4-3). However, as demonstrated in Figure 4-3, the fiber diameter was
far from uniform, and there were significant defects observed in the fibers. In an attempt
to decrease the occurrence of defects and unify the fiber diameter, the electrospinning
parameters were further modified, changing the needle gauge from 22 to 18 or 20, and
decreasing the distance between the needle tip and collector from 10 to 8 cm. Figure 4-4
shows representative SEM images at various concentrations of PCL and CD:IC with the
variation of electrospinning conditions. Although increasing the needle inner diameter has
the overall effect of increasing the fiber diameter, it was hypothesized that by increasing
the thickness of the polymer jet, the CD:IC would be better encompassed in the polymer
matrix, ultimately leading to a decreased occurrence of defects in the fibers. As can be seen
in Figure 4-4, considerably reduced defects and beads on the fibers were observed and the
fibers appeared to be more uniform, if thicker overall.

At this time, it was not possible to incorporate higher amounts of CD:IC into the PCL
polymer matrix while maintaining the desired fiber morphology. At 8PCL-50CD:IC, it
appears as though the CD:IC actually precipitated out of the polymer (Figure 4-5A).
Decreasing the polymer concentration to 5PCL-50CD:IC resulted in a vast amount of
beading (Figure 4-5B). These observations are similar to those made for 5PCU-35CD:IC
(Figure 4-1A) and 8PCU-60CD:IC (Figure 4-1B). It is possible that with further
optimization more CD:IC could be incorporated in order to increase the oxygen delivery
potential of the PCL fibers. At this time, however, the optimized concentration for this
study was determined to be 8PCL-15CD:IC, prepared in a co-solvent system at a 1:1 ratio
of DMF:DCM and electrospun with a 20 gauge needle at a distance of 8 cm between the
needle tip and collector (shown in Figure 4-4B).
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B

C

D

E

F

Figure 4-4: Representative SEM images at 10,000x magnification showing the
reduction in defects when the electrospinning parameters were altered using 1:1
DMF:DCM co-solvent system (A) 8 % (v/v) PCL, 15 % (w/w) CD:IC with 18 gauge
needle at 8 cm (B) 8 % (v/v) PCL, 15 % (w/w) CD:IC with 20 gauge needle at 8 cm
(C) 8 % (v/v) PCL, 20 % (w/w) CD:IC with 20 gauge needle at 8 cm (D) 8 % (v/v)
PCL, 20 % (w/w) CD:IC with 20 gauge needle at 10 cm (E) 8 % (v/v) PCL, 20 %
(w/w) CD:IC with 18 gauge needle at 10 cm (F) 7.5 % (v/v) PCL, 15 % (w/w) CD:IC
with 22 gauge needle at 8 cm
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A

B

Figure 4-5: SEM images at 2,500x magnification showing the defects observed when
a high concentration of CD:IC is incorporated (A) 8% (v/v) PCL, 50% (w/w) CD:IC
(B) 5% (v/v) PCL, 50% CD:IC
The average fiber diameter obtained with the optimized polymer solutions was calculated
using ImageJ software, measuring a total of 100 fibers from three different fields of view.
For 8PCU-50CD:IC, the average fiber diameter was calculated to be (232 ± 31) nm which
is within the range preferred for tissue engineering applications as they are most similar to
the typical diameter of protein fibers in the native ECM.20 The average fiber diameter for
8PCL-15CD:IC was calculated to be (342 ± 56) nm. Although significantly larger than the
fibers fabricated with PCU (p≤0.001), they are still within the acceptable range for tissue
engineering applications.20 Another important feature is that the fibers obtained were
uniform in diameter so that the scaffold can better recreate the functions of the native
ECM.21 Figure 4-6A shows the distribution of fiber diameter in the 8PCU-50CD:IC
electrospun scaffold, demonstrating the relatively narrow distribution and the close fit to
the normal distribution (R2=0.97). In contrast, the fiber diameter distribution for the 8PCL15CD:IC scaffold (Figure 4-6B) was not as narrow and does not follow the normal
distribution as closely (R2=0.90). This can be explained by the difficulties experienced
while electrospinning the PCL-based solutions. Overall, the control over fiber morphology
is important for scaffold designs that better recreate the functions of the native ECM.
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A

B

Figure 4-6: Fiber diameter distribution (N=100) of electrospun
fibers and Gaussian distribution for (A) 8PCU-50CD:IC and (B)
8PCL-15CD:IC
In conclusion, it was possible to incorporate the inclusion complex prepared from α-CD
and PFP in 3D scaffolds via electrospinning. Incorporating cyclodextrin in the polymer
solution had a positive effect on the electrospinning process, enabling successful
electrospinning at low polymer concentrations. It was possible to obtain scaffolds with
acceptable fiber morphology, as determined by SEM, and there was no sign of CD:IC
crystal aggregates on the surface of the fibers. This study provides confirmation of the
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feasibility of incorporating the CD/PFC inclusion complexes in 3D constructs for
application in tissue engineering as oxygen carriers. Arguably the most notable strength of
this study is the potential of incorporating the inclusion complex in a virtually any polymer
matrix through electrospinning. Successful incorporation of the CD:IC was observed with
both the biostable PCU and biodegradable PCL. The optimized concentrations were
determined to be 8PCU-50CD:IC and 5PCL-15CD:IC leading to fiber diameters of (232 ±
31) nm and (342 ± 56) nm, respectively.

Surface Characterization
The scaffolds were characterized by XPS to reveal the elemental analysis up to a depth of
5-7 nm from the surface. Characterization was carried out using polymer and CD:IC
concentrations previously determined to provide fibrous mats with a morphology
acceptable for tissue engineering applications. XPS of the 8PCU-50CD:IC fibrous mat was
compared to that of PCU incorporating unmodified α-CD at the same concentration, that
is 8 % (v/v) PCU and 50 % (w/w) α-CD, and PCU alone, electrospun from a 12 % (v/v)
solution in DMF. Similarly, the 8PCL-15CD:IC fibrous mat was compared to a PCL
scaffold incorporating unmodified α-CD at the same concentration, 8 % (v/v) PCL with 15
% (w/w) α-CD, as well as a PCL control scaffold electrospun from 12 % (w/v) PCL. It was
necessary to electrospin the PCU and PCL control scaffolds at concentrations higher than
the 8 % (v/v) concentration used in the CD:IC-modified scaffolds because the polymer
concentration was too low for successful electrospinning without incorporating CD.

The elemental analysis obtained from XPS is provided in Table 4-3 and the corresponding
spectra are shown in Appendix 6-1. In both the PCU-CD and PCU-CD:IC fibers, a higher
oxygen content is observed, confirming the presence of CD within the outer surface of the
fibrous mat. However, the increase in surface content of oxygen is lower than the amount
of CD incorporated. This indicates that a portion of the CD molecules are buried in the
bulk of the fibers, similar to results reported in the literature for PS/CD nanofibers9, 12 The
increase in oxygen content is much less obvious for the PCL-CD and PCL-CD:IC
nanofibers because only 15 % (w/w) CD or CD:IC was incorporated in the PCU fibers
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compared to the 50 % (w/w) concentration of CD or CD:IC in the PCU fibers. No fluorine
content is observed in the fibers containing the CD:IC because it is buried inside both the
CD:IC cavity and the polymer matrix and is therefore not detected by the survey scan.

Because some of the CD:IC is buried in the bulk of the fibers, there is a benefit of using a
biodegradable polymer matrix. For instance, as the PCL degrades, the CD:IC embedded
within the fibrous matrix would gradually be exposed. By contrast, with a biostable
polymer matrix, such as PCU, only the inclusion complexes on the surface of the fibers
would be available for use as oxygen carriers and only if they are not completely covered
by the polymer. Therefore, utilizing a biodegradable polymer guarantees the availability of
the CD:IC over the course of an in vitro cell cultivation. It is also possible that the
experimental parameters could be further optimized in order to obtain highly efficient
fibers with a high CD content on the surface of the fibers. This may be achieved by varying
the electrospinning temperature or the solvent system, for example, or by using chemically
modified CD derivatives which have been reported to phase segregate to the fiber surface
during solvent evaporation.12

Table 4-3: Elemental analysis from XPS spectra showing atomic % of each element
observed
Sample

C%

O%

N%

α-CD
CD:IC
PCU
PCU-CD

57.6
58.4
71.2
58.4

42.4
41.4
25.1
41.3

3.7
0.3

PCU-CD:IC

60.9

38.0

1.0

PCL
PCL-CD
PCL-CD:IC

74.8
72.9
74.6

25.2
27.1
25.4

F%
0.2
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4.5 Conclusion
In this study, a CD:IC prepared from α-CD and PFP was incorporated into 3D scaffolds
with the ultimate goal of improving oxygen delivery in tissue engineering applications.
Electrospinning was used as the fabrication technique, and both stable and biodegradable
polymer matrices were studied: PCU and PCL, respectively. Incorporating cyclodextrin in
the polymer solutions showed a positive effect on electrospinning, allowing for successful
electrospinning of bead-free fibers from low polymer concentrations, as expected based on
previous studies.10, 11 This is because the addition of CD increases the conductivity of the
polymer solution causing the polymer solution to be subjected to higher stretching under
the high electric field.12 The CD:IC was successfully incorporated within both polymers
producing bead-free, uniform fibers with suitable diameters for tissue engineering
applications, as determined by SEM images. It was possible to incorporate up to 50 %
(w/w) CD:IC in the PCU fibers but only 15 % (w/w) CD:IC in the PCL fibers. The average
fiber diameters of the scaffolds were determined to be (232 ± 31) nm and (342±56) nm for
PCU-CD:IC and PCL-CD:IC, respectively, which is within the acceptable margin for most
tissue engineering applications.20

The CD:IC-functionalized scaffolds were further characterized using XPS. An increase in
oxygen content was observed when compared to PCU and PCL control scaffolds which
confirms the incorporation of α-CD within the fibers. It was determined that a large amount
of CD:IC was buried within the bulk of the fibers. This suggests that a biodegradable
polymer matrix, such as PCL, may be better for cell culturing as the CD:IC buried within
the bulk of the fibers would be exposed as the scaffold material degrades. Overall, these
results provided the proof of concept necessary to support further studies on the in vitro
ability of these functionalized fibers to enhance oxygen delivery to seeded cells.
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5 IN VITRO ANALYSIS OF OXYGEN DELIVERY OF
CYCLODEXTRIN INCLUSION COMPLEXES WITH
PERFLUOROPERHYDROPHENANTHRENE
Overview: This chapter discusses the in vitro analysis of the effect of inclusion complexes
prepared from alpha-cyclodextrin and perfluoroperhydrophenanthrene on dissolved
oxygen. Studies were carried out both in solution and on 3D scaffolds incorporating the
inclusion complex. Preliminary degradation studies were also carried out on the CD:ICfunctionalized 3D scaffolds.

Keywords: dissolved oxygen, oxygen delivery, tissue engineering, 3D scaffold,
cyclodextrin, inclusion complex, perfluorocarbon

5.1 Introduction
Scaffold-guided tissue engineering continues to emerge as a strategy for the repair and
regeneration of diseased or damaged tissues and organs as an alternative to current
therapies.1 However, one of the major factors hindering the success of scaffold-guided
tissue engineering is the inability to deliver sufficient oxygen to the growing constructs.
Although numerous strategies have been developed to overcome this limitation, they have
been riddled with drawbacks; thus delivering sufficient oxygen remains a fundamental
consideration for fabricating engineered tissues. 2-4 One approach to improve oxygen
delivery to constructs is the use of perfusion bioreactors whereby oxygen dissolved in the
culture medium diffuses to the scaffold material. However, the flow rate required to
maintain an adequate oxygen concentration for cell viability often surpasses the shear stress
tolerance of cells.5 Alternatively, perfluorocarbons have been extensively explored as
oxygen carriers due to their high dissolving power for oxygen, though the focus has been
on fabricating perfluorocarbon emulsions which lack stability and are overall userunfriendly.6 Moreover, the high density of the emulsions causes them to settle in the culture
well or medium reservoir.7 An alternative strategy involves embedding oxygen generating
compounds, such as calcium peroxide8 or sodium percarbonate9 which decompose in water
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to produce oxygen, directly into the tissue engineering scaffold. This approach has the
advantage of providing oxygen throughout the construct, specifically in the center where
it is difficult to reach by diffusion alone, but it is limited as the oxygen generating
compound is eventually depleted. Tissue engineering scaffolds incorporating fluorinated
porous zeolite particles provide an alternative to this approach whereby the embedded
compound does not generate oxygen but enhances its delivery using the principles of
oxygen solubility in PFCs.10

In this work, cyclodextrin inclusion complexes with perfluorocarbons have been prepared
for application as oxygen carriers in tissue engineering. Because inclusion of a guest
molecule within the cyclodextrin cavity can provide stabilization, it may serve to overcome
some of the shortcomings of PFC emulsions. Moreover, the complexes have been
successfully incorporated in 3D scaffolds via electrospinning. This would impart enhanced
oxygen delivery throughout the construct, and delay or prevent settling of the PCFs in the
culture well or medium reservoir. It was possible to incorporate the CD/PFC complexes in
both biostable (PCU) and biodegradable (PCL) polymer matrices while maintaining
acceptable fiber morphology for tissue engineering. This study explores the ability of the
cyclodextrin/perfluorocarbon inclusion complexes to act as oxygen carriers in terms of
their ability to increase dissolved oxygen.

5.2 Materials
Perfluoroperhydrophenanthrene (PFP, mixture of isomers, 83 % purity) and alphacyclodextrin (α-CD, 100 % purity) were obtained commercially from Alfa Aesar (Ward
Hill, MA). Solvents were purchased from Caledon Labs (Georgetown, ON). Span80
(C24H44O6) was used as a surfactant and was purchased from Sigma Aldrich (Milwaukee,
WI). All other chemicals were purchased from Sigma Aldrich. Unless noted otherwise, all
chemicals were used as received without any further modification.
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5.3 Methods
Preparation of Inclusion Complex
Weighed amounts of α-CD and a minimal amount of d.i. water were combined to form a
paste. Weighed amounts of PFP were added to the α-CD paste at a 2:1 α-CD to PFP molar
ratio. The paste was thoroughly mixed using a ceramic mortar and pestle for ten minutes.
The product was collected in a glass vial, dried and stored in a desiccator with potassium
hydroxide as a desiccant. The products were analyzed with FTIR as discussed previously
(Section 3.3.3) to ensure successful complexation consistent with previous results (Section
3.4.2)

Fabricating 3D Scaffolds
Fibrous mats were prepared from PCU and PCL via electrospinning, at the optimized
concentrations and conditions described in Section 4.4.1. PCU-CD:IC was electrospun at
a concentration of 8 % (v/v) in DMF with 50 % (w/w) CD:IC incorporated, using a 22
gauge stainless steel needle at a distance of 8 cm from the needle tip to collector. A PCU
control was electrospun at a concentration of 12 % (v/v) in DMF using a 22 gauge stainless
steel needle at a distance of 8 cm from the needle tip to collector. PCL-CD:IC was
electrospun at a concentration of 8 % (v/v) in 1:1 DMF:DCM with 15 % (w/w) CD:IC
incorporated using a 20 gauge stainless steel needle at a distance of 8 cm from the needle
tip to collector. A PCL control was electrospun at a concentration of 12 % (w/v) in 1:1
DMF:DCM using a 22 gauge stainless steel needle at a distance of 10 cm from the needle
tip to collector.

The viscous polymer solution was transferred to a 0. 5 mL glass syringe which was then
fixed horizontally on a syringe pump (KD101, KD Scientific, USA). The flow rate was
maintained at 0.2 mL/h and connected to a high voltage supply (ES30P, Gamma High
Voltage, USA) which applied a voltage of 15 kV. The polymer solution was refilled every
2.5 hours to electrospin a total volume of 3 mL. The fibers were collected on a grounded
rotating mandrel collector which was covered with aluminum foil and a dryer sheet and
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rotated at roughly 2000 RPM. Following this, the scaffolds were removed from the
electrospinning assembly and the solvent was allowed to evaporate in the fume hood.

Dissolved Oxygen Study on Cyclodextrin Inclusion Complexes with
Perfluoroperhydrophenanthrene
The dissolved oxygen was measured using a fiber optic oxygen sensor, NeoFox model
FOXY-AL300 (Ocean Optics, Dunedin, FL), equipped with NeoFox software. The sensor
uses ruthenium (II) complexes suspended in a support matrix and attached at the tip of a
fiber optic cable. When excited by a light emitting diode at 475 nm, the ruthenium complex
fluoresces and emission occurs at 620 nm. When the excited ruthenium complex
encounters an oxygen molecule, the emission is quenched, allowing the intensity of the
fluorescence to be related to the oxygen concentration. Accordingly, the more oxygen that
is present, the lower the emission intensity and vice versa. In the absence of oxygen, the
maximum fluorescent intensity of emitted light is observed. A multipoint calibration was
carried out using the factory calibration file provided by Ocean Optics, followed by a single
point reset at standard temperature and pressure, and 20.9 % oxygen. The oxygen sensor
was placed in the solution and measured dissolved oxygen every 0.5 seconds.
Various concentrations (1, 2, 4 %) of PFP, α-CD, and CD:IC, with respect to the PFP
concentration within complex, were suspended in phosphate buffered saline (PBS; pH 7.4)
with and without 0.1 % Span80 as a surfactant. The samples were rocked for 90 minutes
(Gel Surfer, DiaMed Supplies Inc., Mississauga, ON). PBS with and without 0.1 % Span80
was used as a control. The 300 nm diameter probe was placed in the solution while the
assembly was left open to atmospheric air. Measurements were taken at both RT and 37
°C, maintained by immersing the assembly in a water bath (VWR International,
Mississauga, ON). The dissolved oxygen, measured as the oxygen partial pressure (atm),
was recorded until stable readings were achieved. Henry’s law (Equation 2-6) was used
to determine the oxygen concentration in the solution, and the Henry’s law constant was
determined at each temperature according to Blanch and Clark.11 The samples were stored
in a refrigerator at 4 °C for two weeks, at which point all dissolved oxygen measurements
were taken again at both RT and 37 °C. All measurements were carried out in triplicates.
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Squares of the electrospun fibrous mats (roughly 1 cm2) were weighed, placed in a 24-well
plate and covered with 1 mL of PBS (pH 7.4). The 24-well plates were placed in an
incubating microplate shaker (VWR International, Mississauga, ON) at 37 °C with
continuous shaking at 100 shakes/min. After 1, 3, 5, 7, 10, and 14 days, the dissolved
oxygen was measured using the NeoFox fiber optic oxygen sensor. Following
measurement of dissolved oxygen, the corresponding squares were removed from their
well, dried in a desiccator with potassium hydroxide as a desiccant for 72 hours, and
weighed. The PBS was replenished every 3 days. All measurements were carried out in
triplicates.

Statistical Analysis
The results of the dissolved oxygen studies were analyzed using analysis of variance
(ANOVA) with the Tukey post-test. The Pearson product-moment correlation coefficient
was calculated in SigmaPlot (Systat Software Inc., USA). For all analyses, significance
was assigned for p<0.05.

5.4 Results and Discussion
Dissolved Oxygen Study on Cyclodextrin Inclusion Complexes with
Perfluoroperhydrophenanthrene
The ability of PFP to enhance oxygen delivery to cells seeded on 3D tissue engineering
scaffolds was investigated. Because in vitro data using PFP is not reported, it was
investigated if this molecule could be a candidate to enhance oxygen delivery in tissue
engineering. Furthermore, the feasibility of utilizing the prepared cyclodextrin inclusion
complexes from PFP and α-CD was explored.

Measurements of dissolved oxygen (DO) in the presence of different weight percentages
of PFP, α-CD, and CD:IC were conducted in PBS with a fiber optic probe under a number
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of conditions: with or without surfactant (0.1 % Span80), at RT or 37 °C, and immediately
following sample preparation (Day 1) or after two weeks storage in a refrigerator (Day 14).
It should be noted that the amount of CD:IC incorporated corresponded to the weight
percent of PFP in the inclusion complex, that is, 2 % CD:IC contains 2 % PFP. Table 5-1
shows the results of the DO measurements, reported as dissolved oxygen (mg/L) ± standard
deviation (SD) and the statistical significance of the data, as determined by ANOVA, is
reported in Appendix 7-2.

The DO measured in the PBS controls (Table 5-1) was comparable to the DO calculated
using Henry’s law (8.39 mg/L at 23 °C, 6.87 mg/L at 37 °C). When the dissolved oxygen
was measured immediately following preparation (RT, no surfactant, Day 1), the data
shows that by incorporating 2 % PFP in PBS, there was a significant increase in dissolved
oxygen (p=0.01), whereas 1 % PFP was not sufficient to statistically increase the dissolved
oxygen (p=0.71). This concurs with a previous study in our lab where a minimum threshold
of 2 % perfluorodecalin was required to statistically increase the dissolved oxygen. 10 A
similar relationship was observed with the incorporation of CD:IC, where a minimum
threshold of 2 % was required in order to significantly increase the dissolved oxygen at RT
(p<0.001). When the amount of PFP incorporated was increased from 2 to 4 %, a further
statistically significant increase was observed (p<0.001). On the other hand, when the
amount of CD:IC was likewise increased to 4 %, the dissolved oxygen did not increase
significantly (p=1.00).

This experiment was also carried out at 37 °C, corresponding with body temperature. At
37 °C, for samples both with and without surfactant, incorporation of even 1 % PFP served
to significantly increase the dissolved oxygen in PBS (p<0.001 for both). In both cases,
increasing the concentration from 2 to 4 % resulted in a corresponding increase in dissolved
oxygen (p<0.001 for both). Because they are the most relevant conditions to represent
usage of these oxygen carriers in the human body, Figure 5-1 shows the data for the
dissolved oxygen measurements at 37 °C immediately following sample preparation
(Day1) without the use of surfactant.
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Table 5-1: Dissolved oxygen in PBS at various conditions in the presence of α-CD,
PFP, and CD:IC. Dissolved oxygen was measured with a fiber optic probe. Data are
means (mg/L) ± SD for experiments performed in triplicate.
RT,
No Surfactant,
Day 1

RT,
Surfactant,
Day 1

37 °C,
No Surfactant,
Day 1

37 °C,
Surfactant,
Day 1

PBS
Control

8.64(±0.07)

PBS
Control

8.50(±0.09)

PBS
Control

6.81(±0.03)

PBS
Control

6.92(±0.04)

1% CD
2% CD
4% CD

8.65(±0.03)
8.64(±0.04)
8.66(±0.01)

1% CD
2% CD
4% CD

8.60(±0.03)
8.48(±0.10)
8.67(±0.021)

1% CD
2% CD
4% CD

6.88(±0.02)
6.90 (±0.02)
7.12(±0.04)

1% CD
2% CD
4% CD

6.95(±0.05)
6.94(±0.07)
7.07(±0.027)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

8.73(±0.11)
8.70(±0.05)
8.85(±0.02)
8.96(±0.06)
9.13(±0.08)
8.98(±0.08)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

8.73(±0.03)
8.73(±0.03)
8.89(±0.05)
9.32(±0.04)
9.41(±0.14)
9.63(±0.03)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

7.10(±0.07)
7.29(±0.04)
7.34(±0.08)
7.41(±0.02)
7.63(±0.01)
7.87(±0.02)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

7.14(±0.02)
7.28(±0.03)
7.60(±0.002)
7.69(±0.02)
7.91(±0.02)
7.95(±0.005)

RT,
No Surfactant,
Day 14

RT,
Surfactant,
Day 14

37 °C,
No Surfactant,
Day 14

37 °C,
Surfactant,
Day 14

PBS
Control

7.80(±0.04)

PBS
Control

7.84(±0.08)

PBS
Control

6.66(±0.02)

PBS
Control

6.82(±0.01)

1% CD
2% CD
4% CD

7.62(±0.04)
7.74(±0.07)
8.29(±0.03)

1% CD
2% CD
4% CD

7.80(±0.05)
7.98(±0.02)
8.16(±0.01)

1% CD
2% CD
4% CD

6.78(±0.02)
6.78(±0.02)
6.93(±0.09)

1% CD
2% CD
4% CD

6.92(±0.04)
6.88(±0.02)
6.84(±0.02)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

8.05(±0.03)
7.94(±0.07)
8.02(±0.004)
8.14(±0.04)
8.53(±0.01)
8.66(±0.04)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

8.26(±0.04)
8.36(±0.01)
8.47(±0.01)
8.91(±0.04)
9.29(±0.05)
9.54(±0.04)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

6.91(±0.02)
7.13(±0.02)
7.22(±0.01)
7.32(±0.01)
7.40(±0.01)
7.71(±0.001)

1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

7.04(±0.04)
7.27(±0.01)
7.51(±0.02)
7.61(±0.01)
7.75(±0.01)
7.92(±0.02)

The dissolved oxygen was also measured in samples containing 0.1 % Span80 as a
surfactant, with the same weight percentages of α-CD, PFP, and CD:IC. Relevant statistical
data comparing results obtained with and without the use of surfactant are presented in
Appendix 7-3. Adding a surfactant had a considerable impact on the results at both RT
and 37 °C, as well as on Day 1 and Day 14. Statistically significant increases in dissolved
oxygen were observed in all cases at as low as 1 % for both PFP and CD:IC. This is
specifically notable in comparison to RT, Day 1 conditions where a minimum threshold of
2 % PFP was required to produce a statistically significant increase without surfactant.
These changes can likely be attributed to the emulsifying properties of the surfactant,
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producing a more stable system between the PFP and PBS. Furthermore, increasing the
concentration from 2 to 4 % served to further enhance the dissolved oxygen, in both the
case of PFP and CD:IC under all conditions.

*
*
*

*

*

*

*

Figure 5-1: Dissolved oxygen in PBS (37 °C, no surfactant, Day 1), in the presence of
different weight percentages of α-CD, PFP, and CD:IC. Dissolved oxygen was
measured using a fiber optic probe. Data are means ± SD for experiments conducted
in triplicate, * indicates statistical significance at p<0.05.

Following DO measurements on Day 1, the samples were stored in a refrigerator at 4 °C
for two weeks in order to test the ability of the perfluorinated compounds, specifically in
the form of the inclusion complex, to enhance oxygen delivery after storage. Relevant
statistical data for these long term studies is presented in Appendix 7-4. Most interestingly,
all of the measurements at 37 °C (without surfactant) were statistically comparable to those
taken under the same conditions on Day 1. This indicates that including the PFC in the
cyclodextrin cavity serves to enhance the stability of the PFC. These results are extremely
relevant as one of the main disadvantages of using PFC emulsions is their lack of stability,
resultant stringent storage requirements, and overall lack of user-friendliness.1,

6

Furthermore, with the exception of two conditions, utilizing the CD:IC as opposed to
unmodified PFP actually served to further enhance the dissolved oxygen. For example, at
37 °C (without surfactant, Day 1), the dissolved oxygen was (7.63±0.01) mg/L for 4 %
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PFP and (7.87±0.03) mg/L for 4 % CD:IC, demonstrating a significant difference
(p<0.001).
An interesting trend was observed with the incorporation of 1, 2, and 4 % α-CD when
compared to PBS. At 37 °C (Day 1), both with and without surfactant, incorporation of 4
% α-CD resulted in a statistically significant increase in dissolved oxygen (p<0.001 for
both). After 14 days of storage in a refrigerator at 4 °C, this effect was further enhanced
with increases in dissolved oxygen occurring at both RT and 37 °C as well as with and
without surfactant. Furthermore, the dissolved oxygen was statistically increased with as
low as 1 % α-CD in a number of cases. It has been shown that cyclodextrins can store gases
in their cavity, particularly α-CD because the small size of its cavity suits the low molecular
weight of the gases.12 Cramer and Henglein13 showed that by bubbling various gases, such
as chlorine, xenon, and oxygen in an α-CD/water solution at 7-120 atm, crystalline gas
complexes could be isolated and remained stable for months at room temperature. The
amount of gas complexed varied between 0.3 and 1.2 moles of gas per mole of α-CD and
could be easily evolved by simply dissolving the crystalline complex in water. 12, 14 It is
therefore possible that certain conditions, such as increasing the temperature to 37 °C,
allowed the α-CD to form an inclusion complex with oxygen, effectively increasing the
dissolved oxygen in solution.

Further statistical analysis was carried out on the dissolved oxygen measurements by
computing the Pearson product-moment correlation coefficient in order to determine the
linear dependence of the dissolved oxygen on the concentration of PFP and CD:IC. The
results are presented in Table 5-2 and indicate a clear significant linear relationship
between the concentration of both PFP and CD:IC and dissolved oxygen in all cases. This
relationship demonstrates that as the concentration of PFP or CD:IC is increased, the
dissolved oxygen also increases.
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Table 5-2: Pearson product-moment correlation coefficients and corresponding p
values demonstrating linear dependence of DO on concentration of PFP and CD:IC
PFP

CD:IC

RT,
No Surfactant,
Day 1

PFP

CD:IC

RT
Surfactant
Day 1

PFP

CD:IC

37 °C
No Surfactant
Day 1

PFP

CD:IC

37 °C
Surfactant
Day 1

Correlation
Coefficient

0.94

p value

4.52
E-06

Correlation
Coefficient

0.96

0.99

0.99

0.99

0.96

0.97

0.96

0.97

p value

1.16
E-06

5.50E09

2.65E10

2.20E09

7.47E07

1.06E07

6.17E07

2.98E07

0.84

6.34E04
RT,
No Surfactant
Day 14

0.98

0.96

7.32E- 8.27E08
07
RT
Surfactant
Day 14

0.97

0.97

1.26E- 1.21E07
07
37 °C
No Surfactant
Day 14

0.97

0.96

9.39E- 4.36E08
07
37 °C
Surfactant
Day 14

In summary, the feasibility of utilizing PFP as an oxygen carrier molecule was shown. At
37 °C, as low as 1 % PFP resulted in a significant increase in the dissolved oxygen in PBS
as measured with a NeoFox fiber optic probe. Dissolved gases are transported by
perfluorinated compounds due to increased solubility in accordance with Henry’s Law.
The increased solubility in attributed to the existence of loose, non-directional van der
Waals interactions leading to low cohesive energy densities, which facilitate mutual
solubilization of oxygen in the fluorine compound. The feasibility of using an inclusion
complex prepared from α-CD and PFP was also established. In fact, the CD:IC served to
further increase the dissolved oxygen when compared to the same concentration of PFP at
a number of conditions. Furthermore, including the PFP within the CD cavity was shown
to improve the stability over a period of two weeks when stored in a refrigerator at 4 °C.
Overall, this study indicates that CD:ICs prepared with PFCs can be used as oxygen carriers
to enhance oxygen delivery in tissue engineering applications.
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The feasibility of utilizing a cyclodextrin inclusion complex prepared with a PFC as an
oxygen carrier was explored with promising results. Theoretically, the complexes could be
added directly to the culture media and the effect on dissolved oxygen would be similar to
that reported in the previous section (5.4.1). However, this is not an improvement over
other studies where the PFC was added directly to the culture medium and their high
density caused them to settle, limiting their potential. 7, 15 For this reason, in this study the
CD:ICs were incorporated into a tissue engineering construct, fabricated using the
electrospinning technique. This serves to immobilize the PFC within the scaffold and delay
or prevent settling of the PFC into the culture medium, while providing enhanced oxygen
delivery throughout the construct, specifically in the center where it is difficult for oxygen
to permeate by diffusion alone.

Two different materials were explored as polymer matrices for fabricating the tissue
engineering constructs incorporating the CD:IC. PCU and PCL were selected as stable and
biodegradable polymers, respectively. The constructs were fabricated via electrospinning
from concentrations optimized previously (Section 4). The optimized concentration for
PCU was 8 % (v/v) PCU with respect to solvent and 50 % (w/w) CD:IC with respect to
PCU, referred to as 8PCU-50CD:IC. The optimized concentration for PCL was 8 % (v/v)
PCL with respect to solvent, 15 % (w/w) CD:IC with respect to PCL, referred to as 8PCL15CD:IC. The CD:IC-functionalized scaffolds were compared to scaffolds fabricated from
unmodified PCU and PCL. Squares of the fibrous mats (roughly 1 cm 2) were placed in
PBS at 37 °C and the DO was measured after 1, 3, 5, 7, 10, and 14 days with a fiber optic
probe. Table 5-3 shows the results of these measurements, reported as dissolved oxygen
(mg/L) ± standard deviation. Figure 5-2 and Figure 5-3 graphically depict these
measurements for the PCU- and PCL-based scaffolds, respectively.
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Table 5-3: Dissolved oxygen in PBS in the presence of electrospun 3D fibrous mats
fabricated from PCU or PCL incorporating an inclusion complex prepared from αCD and PFP. Dissolved oxygen was measured with a fiber optic probe. Data are
means (mg/L) ± SD for experiments performed in triplicate.
Day

PCU Control

PCU-CD:IC

PCL Control

PCL-CD:IC

1

6.43(±0.22)

8.47(±0.48)

6.57(±0.20)

8.52(±0.80)

3

7.82(±0.08)

8.07(±0.32)

8.38(±0.18)

9.02(±0.42)

5

8.13(±0.26)

9.71(±0.32)

8.35(±0.33)

9.94(±0.29)

7

8.26(±0.35)

10.9(±0.53)

8.24(±0.87)

9.62(±0.45)

10

7.04(±0.96)

9.38(±0.26)

7.94(±0.42)

9.51(±0.21)

14

7.93(±0.19)

9.63(±0.62)

8.40(±0.12)

10.0(±0.46)

*
*

*
*

Figure 5-2: Dissolved oxygen measurements for PCU and PCU-CD:IC scaffolds in
PBS at 37 °C. Dissolved oxygen was measured using a fiber optic probe. Data are
means ± SD for experiments conducted in triplicate, * indicates statistical significance
at p<0.05
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*

*
*

*

*

Figure 5-3: Dissolved oxygen measurements for PCL and PCL-CD:IC scaffolds in
PBS at 37 °C. Dissolved oxygen was measured using a fiber optic probe. Data are
means ± SD for experiments conducted in triplicate, * indicates statistical significance
at p<0.05

When compared to the PBS control, neither the PCU nor the PCL scaffolds showed any
significant increase in dissolved oxygen at any time point, as expected (statistical data is
presented in Appendix 7-5). As indicated in Figure 5-2, the PCU-CD:IC scaffold showed
a significant increase in DO on Day 5 (p<0.001). Likewise, the PCL-CD:IC scaffold
showed a significant increase in DO on Day 3 (p=0.01), as indicated in Figure 5-3. The
DO was observed to remain significantly increased over the remainder of the 14 day period
in the presence of both PCU-CD:IC and PCL-CD:IC fibrous mats.

Further statistical analysis was carried out on the dissolved oxygen measurements by
computing the Pearson product-moment correlation coefficient in order to determine the
linear dependence of the dissolved oxygen measurement on time. The results are presented
in Table 5-4 and demonstrate a lack of significant linear relationship between time and the
dissolved oxygen measured for all materials except the PCL-CD:IC nanofibers. The PCLCD:IC nanofibers show a significant but weak relationship between the variables, with the
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DO tending to increase with time. Because PCL is a degradable polymer whereas PCU is
not, it is likely that this trend would be further enhanced with a stronger relationship evident
over long-term studies, corresponding to the degradation of PCL.

Table 5-4: Pearson product-moment correlation coefficients for the dissolved oxygen
concentration and time for CD:IC-functionalized scaffolds
PCU Control

PCU-CD:IC

PCL Control

PCL-CD:IC

Correlation
Coefficient

0.29

0.46

0.46

0.61

p value

0.24

0.06

0.05

0.007

Figure 5-4 shows a graphical comparison of the two polymer materials, PCU and PCL
with the CD:IC incorporated, and Appendix 7-6 shows the corresponding statistical
analysis of the DO measurements. There was no statistical difference between the DO
measured in the presence of either material at any time point. This is interesting because it
was possible to incorporate considerably more CD:IC in the PCU fibers than in the PCL
fibers. This may be explained by the fact that PCL is degradable whereas PCU is not, thus
only the complexes on the surface of the PCU-CD:IC fibers were available whereas when
the PCL matrix began to degrade, increasingly more complex was released. Further studies
are necessary to ascertain how the two materials would compare over the long term. It is
predicted that the oxygen delivery provided by the PCL-CD:IC scaffold would exceed that
of the PCU-CD:IC material because it is biodegradable. Over the lifespan of the PCL, (> 2
years)16 CD:IC would become uncovered from the polymer matrix and/or completely
released. This would serve to prolong the improvement of oxygen delivery to the cells
seeded on the construct whereas the CD:IC contained within the PCU fibers would remain
buried throughout the culture time.
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Figure 5-4: Dissolved oxygen measurements for PCU-CD:IC and PCL-CD:IC
scaffolds in PBS at 37 °C. Dissolved oxygen was measured using a fiber optic probe.
Data are means ± SD for experiments conducted in triplicate, * indicates statistical
significance at p<0.05

A preliminary study was carried out in order to ascertain if there was a burst of CD:IC
released from the polymer matrix upon submersion in PBS; the change in mass of the
fibrous mats were studied alongside the DO measurements. The results of this study are
presented in Table 5-5. Any increases in mass can be attributed to precipitation of PBS
salts on the scaffold after they were dried for 72 hours. A desiccator was used instead of
heat to dry to the scaffolds in order to prevent destruction of the inclusion complex and
loss of the PFP guest. Consequently, it is possible that only the surface moisture was
removed such that residual PBS on the fibers would cause a superficial increase in the final
mass of the fibers. Due to the inconsistency in the change in mass of the fibers, the release
of CD:IC from the fibers cannot be commented on conclusively. Nevertheless, it was
observed that overall there was a greater release from the PCU-CD:IC fibers when
compared to the PCU control fibers. Because PCU is not a degradable polymer, this loss
can likely be attributed to the leaching of the CD:IC from the surface of the fibers. A similar
trend was not distinguishable for the PCL-based scaffolds and the results were
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inconclusive. Further studies should be carried out to better ascertain the changes in the
electrospun fibers after submersion in PBS with respect to the release of CD:IC and its
effect on dissolved oxygen. For instance, analysis of SEM images would allow for the
observation of morphological changes occurring in the fibers with mass loss.

Table 5-5: Change in mass (%) recorded for 3D PCU and PCL scaffolds
incorporating CD:IC and their corresponding controls
Day
1
3
5
7
10
14

A
-14.3
5.26
-4.35
3.85
-2.04
-5.71

PCU Control
B
C
Average
-1.85 -19.5
-119
5.56
10.3
7.04
6.25 -2.63
-0.24
9.52
0.00
4.46
4.55
0.00
0.83
0.00
0.00
-1.90

A
-8.33
-14.3
-14.3
-0.36
-20.4
-42.1

PCL Control
B
C
Average
-25.0 -11.1
-14.8
-3.23 -4.55
-7.36
-9.09 -14.3
-12.6
-0.31 -0.29
-0.32
-23.3 -29.0
-24.2
-16.0 -8.33
-22.1

Day
1
3
5
7
10
14

A
-12.5
-30.0
-25.0
-43.4
-37.2
-37.5

PCU-CD:IC
B
C
Average
-23.8 -32.0
-22.8
-36.0 -43.8
-36.6
-35.6 -47.1
-35.9
-41.9 -51.4
-45.6
-38.3 -37.0
-37.5
175
62.8
66.8

A
-33.3
-19.5
-14.3
-20.5
-20.0
128.0

PCL-CD:IC
B
C
Average
-21.2 -27.6
-27.4
-4.17 -5.26
-9.64
-17.0 -14.0
-15.1
-20.4 -26.1
-22.3
-15.4 -16.7
-17.4
16.7 36.7
60.5

Overall, incorporating the CD:IC within 3D electrospun scaffolds resulted in an increase
in the DO measured in the surrounding PBS. The results of this study are promising and
suggest that incorporating CD/PFC inclusion complexes in scaffolds would be an effective
strategy for enhancing the oxygen delivery to cells seeded on the constructs. An increase
in dissolved oxygen was observed with both biostable, PCU, and biodegradable, PCL,
materials. This promotes the idea that this approach is incredibly versatile, such that the
CD:IC could theoretically be incorporated in a plethora of different polymer materials via
electrospinning. Furthermore, these results indicate that at least some of the CD:IC
embedded within the constructs was on the surface of the fibers and available for oxygen
delivery. This correlates with the data obtained from XPS (Section 4.4.2) which

105

demonstrated that there was increased oxygen content on the surface of the fibers.
Although this study served as a proof of concept, further studies are required in order to
ascertain the ability of these scaffolds to enhance oxygen delivery in the long term.

5.5 Conclusion
One unsolved problem in tissue engineering is overcoming the diffusional limitations of
oxygen which lead to hypoxia in the center of tissue engineering constructs. In this study,
the feasibility of using PFP as an oxygen carrier, specifically in the form of a cyclodextrin
inclusion complex, was explored. Dissolved oxygen concentration significantly increased
in the presence of PFP at all conditions tested, with as low as 1% PFP required for a
statistically significant increase in most cases. At a number of conditions, it was observed
that incorporating the PFP in the form of a cyclodextrin inclusion complex actually served
to further enhance the dissolved oxygen in solution. Moreover, including the PFP within
the α-CD cavity served to enhance the stability of the PFP and the complexes provided a
statistically significant increase in DO after storage in the refrigerator for 2 weeks.

The CD:IC was then embedded in 3D PCU and PCL scaffolds fabricated via
electrospinning. Dissolved oxygen concentration increased in PBS in the presence of these
scaffolds on Day 3 for PCL-CD:IC and Day 5 for PCU-CD:IC, and remained statistically
higher than the PBS control for both materials over the remainder of the 14 day period.
This indicates that at least some of the CD:IC remained available for oxygen delivery when
contained within the polymer matrix.

Taken together, these data suggest the potential for scaffolds functionalized with CD:IC to
enhance oxygen delivery to seeded cells for application in tissue engineering. Incorporating
the oxygen carrier directly in the scaffold enables the delivery of oxygen throughout the
construct, especially in the center where it is difficult to reach by diffusion alone.
Furthermore, it is an improvement upon using PFCs and their emulsions directly in the
culture media because the oxygen carriers are embedded within the scaffold and therefore
will not settle in the media.
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6 GENERAL DISCUSSION AND CONCLUSIONS
Overview: This chapter provides a general summery of the overall work of this thesis as
per the specific objectives mentioned in Section 2.5. The strengths and limitations of this
work are summarized with directions for future work. Finally, the overall significance of
this work for tissue engineering is included.

6.1 Conclusions
The main goal of this study was to enhance the delivery of oxygen to cells seeded on
scaffolds for application in tissue engineering. The fundamental basis for the strategy
explored was the ability of PFCs to transport large quantities of oxygen due to increased
solubility according to Henry’s Law. The initial step involved preparing an inclusion
complex between cyclodextrin and a perfluorocarbon. Specifically, α-CD and PFP were
selected as the host and guest, respectively, following preliminary experiments and
according to the close match between the dimensions of the α-CD cavity and PFP diameter.
Of the numerous complexation techniques available, co-precipitation, paste mixing, and
dry mixing were conducted. The products were characterized with FTIR, TGA, and XRD
in order to establish the most effective complexation technique for the specific host and
guest molecules utilized. Taken together, the characterization techniques showed that paste
mixing and dry mixing, at a molar ratio of 2:1 α-CD to PFP, were the most effective
complexation techniques. Further tests were conducted with the CD:IC prepared by paste
mixing.

The next step involved incorporating the CD:IC into a 3D tissue engineering construct.
Electrospinning was selected as the fabrication technique, with PCU and PCL as the stable
and biodegradable polymer matrices, respectively. SEM micrographs were used to
characterize the resulting fibrous mats in terms of fiber diameter and uniformity. The
optimized concentrations were determined to be 8 % (v/v) PCU with respect to solvent, 50
% (w/w) CD:IC with respect to polymer and 8 % (v/v) PCL with respect to solvent, 15 %
(w/w) CD:IC with respect to polymer. The fibers in these mats had average diameters of
(232 ± 31) nm and (342±56) nm for PCU-CD:IC and PCL-CD:IC, respectively, which is
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within the acceptable margin for most tissue engineering applications. XPS survey scans
of the fibers indicated that at least some of the CD:IC was present on the surface of both
the PCU and PCL fibers.

Finally, the ability of the CD:IC and the CD:IC-containing scaffolds to enhance oxygen
delivery in vitro was studied. Dissolved oxygen, measured with a fiber optic probe in PBS,
was significantly increased in the presence of as low as 1 % PFP. Furthermore, in some
cases incorporating the PFC as a CD:IC actually served to further enhance the dissolved
oxygen. After being embedded within a polymer matrix and electrospun into a 3D fibrous
mat, the CD:ICs maintained their ability to enhance the oxygen delivery. Statistically
significant increases in dissolved oxygen measured in the PBS surrounding the fibrous
mats were observed for both the PCU- and PCL-based materials on Day 5 and 3,
respectively. This increase was maintained over the remainder of the 14 day period of the
experiment for both materials.

Taken together, the experiments conducted over the course of this study demonstrate that
CD:ICs prepared with a PFC are viable oxygen carriers. Embedding the CD/PFC inclusion
complexes within a 3D scaffold is a feasible approach to enhance oxygen delivery to cells
seeded on tissue engineering constructs with the ultimate goal of developing clinically
thick tissues.

6.2 Strengths and Limitations
In this study, a strategy for enhancing oxygen delivery in scaffold-guided tissue
engineering was developed. The strategy involved incorporating cyclodextrin inclusion
complexes with perfluorocarbons as oxygen carriers in tissue engineering scaffolds. One
of the strengths of this approach is that by incorporating the PFC within the CD cavity, the
limitations with stability and user-friendliness of PFC emulsions are overcome. Moreover,
incorporating the oxygen carriers directly within the scaffold prevents, or at least hinders,
the settling of the PFC droplets in either the culture well or medium reservoir. Having the
CD:ICs embedded directly in the scaffold also serves to provide enhanced oxygen delivery
throughout the scaffold, particularly in the center which is difficult to reach by diffusion
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alone. Furthermore, the advantage of using CD/PFC complexes over oxygen generating
compounds, such as calcium peroxide1 or sodium percarbonate,2 is that they are not
depleted and theoretically have an unlimited lifespan.

One of the major strengths with the use of a cyclodextrin/perfluorocarbon inclusion
complex as an oxygen carrier is that there is potential to incorporate the CD:IC within
virtually any polymer via electrospinning. In this study alone, it was possible to embed the
CD:ICs within both stable and degradable polymer matrices. Additionally, the application
of the CD:ICs as oxygen carriers could be extended to other biomaterials; for example,
hydrogels containing cyclodextrin have been reported.3-5 Another advantage of utilizing
cyclodextrin as the oxygen carrier is that cyclodextrins are natural and relatively non-toxic,
making them suitable for biological applications, they have a low price, and are
commercially available.6 In the body, CDs are mainly excreted in their intact form by renal
filtration as they are minimally susceptible to hydrolytic cleavage or degradation by human
enzymes.7

A limitation of this work is the absence of in vitro cell studies. Preliminary cell culture
experiments were carried out on the CD:IC-functionalized fibrous mats (Appendix 7-7),
however, they were not comprehensive enough to conclusively draw conclusions on the
cytotoxicity of the α-CD/PFP inclusion complex. Although CD is well-known to be
relatively non-toxic,6 PFC emulsions are generally considered to be cytotoxic to cultured
human fibroblast cells in a concentration-dependent manner.8,

9

Previous experiments

carried out in our lab on HCASMCs, on the other hand, demonstrated cell viability in the
presence of perfluorodecalin.10 In future work, it is therefore necessary to clarify the
cytotoxicity of the PFC used in this study in the form of a cyclodextrin inclusion complex
embedded within 3D tissue engineering constructs.

Another limitation of this work is the lack of characterization for the complexes prepared
from all techniques attempted. As the ultimate objective of this work was to test the ability
of the inclusion complex to enhance oxygen delivery when embedded within a tissue
engineering scaffold, once sufficient characterization was carried out to confirm complex
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formation the focus was shifted to fabricating the scaffolds and carrying out analysis in
vitro. Theoretically, an entire thesis work could be dedicated to varying the parameters
associated with each complexation technique and thoroughly characterizing the resulting
products.

6.3 Future Directions
In light of the work presented here, future work on this project should include:


Short-term in vitro cell studies on the electrospun fibers incorporating CD:IC to
evaluate cytotoxicity and cell spreading



Long-term in vitro cell studies on the 3D PCU-CD:IC and PCL-CD:IC scaffolds to
further explore their capacity to enhance oxygen delivery, specifically in terms of
increased proliferation overall and decreased necrosis in the center of the construct



Long-term studies to investigate the release of the CD:IC from the degradable PCL
and stable PCU scaffolds



Further characterization of the PCU-CD:IC and PCL-CD:IC scaffolds to clarify the
positioning of the CD:IC in the fibers



Mechanical testing on the 3D PCU-CD:IC and PCL-CD:IC scaffolds to ensure
appropriateness for tissue engineering applications



Electrospinning with different polymers and further research different types of
biomaterials in order to confirm the versatility of this approach

6.4 Significance
The focus of this research was the development of a novel inclusion complex, prepared
between α-cyclodextrin and perfluoroperhydrophenanthrene, and the incorporation of the
inclusion complex in three-dimensional scaffolds. This study serves as the foundation for
the use of cyclodextrin/perfluorocarbon inclusion complexes as oxygen carriers in
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scaffold-guided tissue engineering. Alternative oxygen delivery strategies utilizing
different cyclodextrins, perfluorocarbons, scaffold polymers, or fabrication techniques
may yet be developed.
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7 APPENDICES
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Appendix 6-1: XPS spectra of the unmodified α-CD and prepared CD:IC, and the 3D
PCU and PCL scaffolds incorporating the α-CD and CD:IC
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Appendix 7-2: Statistical data for dissolved oxygen measurements in PBS at various
conditions in the presence of α-CD, PFP, and α-CD/PFP CD:ICs. Dissolved oxygen
was measured with a fiber optic probe. Data are means ± SD for experiments
performed in triplicate. Statistical significance: x indicates p>0.05, * indicates p≤0.05.
*** indicates p≤0.001.

PBS Control vs.

RT, No Surfactant, Day 1
8.64(±0.07)
1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

8.73(±0.11)
8.70(±0.05)
8.85(±0.02)
8.96(±0.06)
9.13(±0.08)
8.98(±0.08)

0.71
0.96
0.01
<0.001
<0.001
<0.001

x
x
*
***
***
***

PBS Control vs.

8.64(±0.07)

1% CD
2% CD
4% CD

8.65(±0.03)
8.64(±0.04)
8.66(±0.006)

1
1
1

x
x
x

1% CD vs.
2% CD vs.
4% CD vs.

8.65(±0.03)
8.64(±0.04)
8.66(±0.01)

1% CD:IC
2% CD:IC
4% CD:IC

8.70(±0.05)
8.97(±0.06)
8.98(±0.08)

0.99
<0.001
<0.001

x
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.
2% CDIC vs.
4% PFP vs.

8.70(±0.05)
8.85(±0.02)
8.85(±0.02)
8.96(±0.06)
9.13(±0.08)

2% CD:IC
2% CD:IC
4% PFP
4% CD:IC
4% CD:IC

8.96(±0.06)
8.96(±0.06)
9.13(±0.08)
8.98(±0.08)
8.98(±0.08)

0.001
0.42
<0.001
1
0.18

***
x
***
x
x

8.73(±0.03)
8.73(±0.03)
8.89(±0.05)
9.32(±0.04)
9.41(±0.14)
9.63(±0.03)

0.01
0.01
<0.001
<0.001
<0.001
<0.001

*
*
***
***
***
***

PBS Control vs.

RT, Surfactant, Day 1
8.50(±0.09)
1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

PBS Control vs.

8.50(±0.09)

1% CD
2% CD
4% CD

8.60(±0.03)
8.48(±0.10)
8.67(±0.02)

0.64
1
0.11

x
x
x

1% CD vs.
2% CD vs.
4% CD vs.

8.60(±0.03)
8.48(±0.10)
8.67(±0.02)

1% CD:IC
2% CD:IC
4% CD:IC

8.73(±0.03)
9.32(±0.04)
9.63(±0.03)

0.48
<0.001
<0.001

x
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.

8.73(±0.03)
8.89(±0.05)
8.89(±0.05)

2% CD:IC
2% CD:IC
4% PFP

9.32(±0.04)
9.32(±0.04)
9.41(±0.14)

<0.001
<0.001
<0.001

***
***
***
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2% CDIC vs.
4% PFP vs.
PBS Control vs.

9.32(±0.03)
9.41(±0.137)

4% CD:IC
4% CD:IC

9.63(±0.03)
9.63(±0.0299)

37°C, No Surfactant, Day 1
6.81(±0.03)
1% PFP
7.10(±0.07)
1% CD:IC
7.29(±0.04)
2% PFP
7.34(±0.08)
2% CD:IC
7.41(±0.02)
4% PFP
7.63(±0.01)
4% CD:IC
7.87(±0.02)

<0.001
0.02

***
*

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

***
***
***
***
***
***

PBS Control vs.

6.806(±0.0333)

1% CD
2% CD
4% CD

6.88(±0.02)
6.90(±0.02)
7.12(±0.04)

0.06
0.25
<0.001

x
x
***

1% CD vs.
2% CD vs.
4% CD vs.

6.879(±0.0238)
6.899(±0.0167)
7.118(±0.038)

1% CD:IC
2% CD:IC
4% CD:IC

7.29(±0.04)
7.41(±0.02)
7.87(±0.02)

<0.001
<0.001
<0.001

***
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.
2% CDIC vs.
4% PFP vs.

7.288(±0.0397)
7.343(±0.0809)
7.343(±0.0809)
7.414(±0.0244)
7.632(±0.0119)

2% CD:IC
2% CD:IC
4% PFP
4% CD:IC
4% CD:IC

7.41(±0.02)
7.41(±0.02)
7.63(±0.01)
7.87(±0.02)
7.87(±0.02)

0.04
0.60
<0.001
<0.001
<0.001

*
x
***
***
***

7.14(±0.02)
7.28(±0.03)
7.60(±0.002)
7.69(±0.02)
7.91(±0.02)
7.95(±0.005)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

***
***
***
***
***
***

PBS Control vs.

37°C, Surfactant, Day 1
6.925(±0.0423)
1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

PBS Control vs.

6.925(±0.0423)

1% CD
2% CD
4% CD

6.95(±0.05)
6.94(±0.07)
7.07(±0.03)

0.99
1
0.001

x
x
***

1% CD vs.
2% CD vs.
4% CD vs.

6.953(±0.0467)
6.942(±0.0668)
7.071(±0.0270)

1% CD:IC
2% CD:IC
4% CD:IC

7.28(±0.03)
7.69(±0.02)
7.95(±0.005)

<0.001
<0.001
<0.001

***
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.
2% CDIC vs.
4% PFP vs.

7.281(±0.03)
7.602(±0.00210)
7.602(±0.00210)
7.687(±0.0165)
7.906(±0.0240)

2% CD:IC
2% CD:IC
4% PFP
4% CD:IC
4% CD:IC

7.69(±0.02)
7.69(±0.02)
7.91(±0.02)
7.95(±0.005)
7.95(±0.005)

<0.001
0.12
<0.001
<0.001
0.8

***
x
***
***
x

RT, No Surfactant, Day 14
7.81(±0.04)
1% PFP
8.05(±0.03)

<0.001

***

PBS Control vs.
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1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

7.94(±0.07)
8.02(±0.004)
8.14(±0.04)
8.53(±0.006)
8.66(±0.04)

0.02
<0.001
<0.001
<0.001
<0.001

*
***
***
***
***

PBS Control vs.

7.80(±0.04)

1% CD
2% CD
4% CD

7.62(±0.04)
7.74(±0.07)
8.29(±0.03)

0.001
0.76
<0.001

***
x
***

1% CD vs.
2% CD vs.
4% CD vs.

7.62(±0.04)
7.74(±0.07)
8.29(±0.03)

1% CD:IC
2% CD:IC
4% CD:IC

7.94(±0.07)
8.14(±0.04)
8.66(±0.04)

<0.001
<0.001
<0.001

***
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.
2% CDIC vs.
4% PFP vs.

7.94(±0.07)
8.02(±0.004)
8.02(±0.004)
8.14(±0.04)
8.53(±0.006)

2% CD:IC
2% CD:IC
4% PFP
4% CD:IC
4% CD:IC

8.14(±0.04)
8.14(±0.04)
8.53(±0.006)
8.66(±0.04)
8.66(±0.04)

<0.001
0.05
<0.001
<0.001
0.04

***
*
***
***
*

8.26(±0.04)
8.36(±0.01)
8.47(±0.01)
8.91(±0.04)
9.29(±0.05)
9.54(±0.04)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

***
***
***
***
***
***

PBS Control vs.

RT, Surfactant, Day 14
7.84(±0.08)
1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

PBS Control vs.

7.84(±0.08)

1% CD
2% CD
4% CD

7.80(±0.05)
7.98(±0.02)
8.16(±0.01)

0.97
0.01
<0.001

x
*
***

1% CD vs.
2% CD vs.
4% CD vs.

7.80(±0.05)
7.98(±0.02)
8.16(±0.01)

1% CD:IC
2% CD:IC
4% CD:IC

8.36(±0.01)
8.91(±0.04)
9.54(±0.04)

<0.001
<0.001
<0.001

***
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.
2% CDIC vs.
4% PFP vs.

8.36(±0.01)
8.47(±0.01)
8.47(±0.01)
8.91(±0.04)
9.29(±0.05)

2% CD:IC
2% CD:IC
4% PFP
4% CD:IC
4% CD:IC

8.91(±0.04)
8.91(±0.04)
9.29(±0.05)
9.54(±0.04)
9.54(±0.04)

<0.001
<0.001
<0.001
<0.001
<0.001

***
***
***
***
***

37°C, No Surfactant, Day 14
6.66(±0.02)
1% PFP
6.91(±0.02)
1% CD:IC
7.13(±0.02)
2% PFP
7.22(±0.01)
2% CD:IC
7.32(±0.01)
4% PFP
7.40(±0.01)

<0.001
<0.001
<0.001
<0.001
<0.001

***
***
***
***
***

PBS Control vs.
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4% CD:IC

7.71(±0.01)

<0.001

***

PBS Control vs.

6.66(±0.02)

1% CD
2% CD
4% CD

6.78(±0.02)
6.78(±0.02)
6.93(±0.09)

0.004
0.01
<0.001

*
*
***

1% CD vs.
2% CD vs.
4% CD vs.

6.78(±0.02)
6.78(±0.02)
6.93(±0.09)

1% CD:IC
2% CD:IC
4% CD:IC

7.13(±0.02)
7.32(±0.01)

<0.001
<0.001
<0.001

***
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.
2% CDIC vs.
4% PFP vs.

7.13(±0.02)
7.22(±0.01)
7.22(±0.01)
7.32(±0.01)
7.40(±0.01)

2% CD:IC
2% CD:IC
4% PFP
4% CD:IC
4% CD:IC

7.32(±0.01)
7.32(±0.01)
7.40(±0.01)
7.71(±0.01)
7.71(±0.01)

<0.001
0.04
<0.001
<0.001
<0.001

***
*
***
***
***

7.04(±0.04
7.27(±0.01)
7.51(±0.02)
7.61(±0.01)
7.75(±0.01)
7.92(±0.02)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

***
***
***
***
***
***

PBS Control vs.

37°C, Surfactant, Day 14
6.82(±0.01)
1% PFP
1% CD:IC
2% PFP
2% CD:IC
4% PFP
4% CD:IC

PBS Control vs.

6.82(±0.01)

1% CD
2% CD
4% CD

6.92(±0.04)
6.88(±0.02)
6.84(±0.02)

0.01
0.16
0.50

*
x
x

1% CD vs.
2% CD vs.
4% CD vs.

6.92(±0.043)
6.88(±0.02)
6.84(±0.02)

1% CD:IC
2% CD:IC
4% CD:IC

7.27(±0.01)
7.61(±0.01)
7.92(±0.02)

<0.001
<0.001
<0.001

***
***
***

1% CD:IC vs.
2% PFP vs.
2% PFP vs.
2% CDIC vs.
4% PFP vs.

7.27(±0.01)
7.51(±0.02)
7.51(±0.02)
7.61(±0.01)
7.75(±0.01)

2% CD:IC
2% CD:IC
4% PFP
4% CD:IC
4% CD:IC

7.61(±0.01)
7.61(±0.01)
7.75(±0.01)
7.92(±0.02)
7.92(±0.02)

<0.001
0.004
<0.001
<0.001
<0.001

***
*
***
***
***
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Appendix 7-3: Statistical data showing the effect of surfactant on dissolved oxygen
measurements in PBS at various conditions in the presence of α-CD, PFP, and αCD/PFP CD:ICs. Dissolved oxygen was measured with a fiber optic probe. Data are
means ± SD for experiments performed in triplicate. Statistical significance: x
indicates p>0.05, * indicates p≤0.05. *** indicates p≤0.001.
No Surfactant

Surfactant

p value

Significance

RT, Day 1
PBS Control

8.64(±0.07)

8.50(±0.09)

0.52

x

1% CD

8.65(±0.03)

8.60(±0.03)

1.00

x

2% CD

8.64(±0.04)

8.48(±0.10)

0.38

*

4% CD

8.66(±0.01)

8.67(±0.02)

1.00

x

1% PFP

8.73(±0.11)

8.73(±0.03)

1.00

x

1% CD:IC

8.70(±0.04)

8.73(±0.03)

1.00

x

2% PFP

8.85(±0.02)

8.89(±0.05)

1.00

x

2% CD:IC

8.97(±0.06)

9.32(±0.04)

<0.001

***

4% PFP

9.13(±0.08)

9.41(±0.14)

<0.001

***

4% CD:IC

8.98(±0.08)

9.63(±0.03)

<0.001

***

37°C, Day 1
PBS Control

6.81(±0.03)

6.92(±0.04)

0.05

x

1% CD

6.88(±0.02)

6.95(±0.05)

0.67

x

2% CD

6.90(±0.02)

6.94(±0.07)

1

x

4% CD

7.12(±0.04)

7.07(±0.03)

0.99

x

1% PFP

7.10(±0.07)

7.14(±0.02)

1.00

x

1% CD:IC

7.29(±0.04)

7.28(±0.03)

1.00

x

2% PFP

7.34(±0.08)

7.60(±0.002)

<0.001

***

2% CD:IC

7.41(±0.02)

7.69(±0.02)

<0.001

***

4% PFP

7.63(±0.01)

7.91(±0.02)

<0.001

***

4% CD:IC

7.868(±0.0207)

7.952(±0.00461)

0.461

x
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RT, Day 14
PBS Control

7.80(±0.04)

7.84(±0.08)

1

x

1% CD

7.62(±0.04)

7.80(±0.052)

<0.001

***

2% CD

7.74(±0.07)

7.98(±0.02)

<0.001

***

4% CD

8.29(±0.03)

8.16(±0.01)

0.02

*

1% PFP

8.05(±0.03)

8.26(±0.04)

<0.001

***

1% CD:IC

7.94(±0.07)

8.36(±0.01)

<0.001

***

2% PFP

8.02(±0.004)

8.47(±0.01)

<0.001

***

2% CD:IC

8.14(±0.04)

8.91(±0.04)

<0.001

***

4% PFP

8.53(±0.01)

9.29(±0.047)

<0.001

***

4% CD:IC

8.66(±0.04)

9.54(±0.04)

<0.001

***

37°C, Day 14
PBS Control

6.66(±0.02)

6.82(±0.01)

<0.001

***

1% CD

6.78(±0.02)

6.92(±0.04)

<0.001

***

2% CD

6.78(±0.02)

6.88(±0.02)

0.01

*

4% CD

6.93(±0.09)

6.84(±0.02)

0.02

*

1% PFP

6.91(±0.02)

7.04(±0.04)

<0.001

***

1% CD:IC

7.13(±0.02)

7.27(±0.01)

<0.001

***

2% PFP

7.22(±0.01)

7.51(±0.02)

<0.001

***

2% CD:IC

7.32(±0.01)

7.61(±0.01)

<0.001

***

4% PFP

7.40(±0.01)

7.75(±0.01)

<0.001

***

4% CD:IC

7.71(±0.01)

7.92(±0.02)

<0.001

***
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Appendix 7-4: Statistical data showing the effect of storage for 14 days in a
refrigerator on dissolved oxygen measured in PBS in the presence of α-CD, PFP, and
α-CD/PFP CD:ICs. Dissolved oxygen was measured with a fiber optic probe. Data are
means ± SD for experiments performed in triplicate. Statistical significance: x
indicates p>0.05, * indicates p≤0.05. *** indicates p≤0.001.
Day 1

Day 14

p value

Significance

RT, No Surfactant
PBS Control

8.64(±0.07)

7.80(±0.044)

<0.001

***

1% CD

8.65(±0.03)

7.62(±0.04)

<0.001

***

2% CD

8.64(±0.04)

7.74(±0.07)

<0.001

***

4% CD

8.66(±0.01)

8.29(±0.03)

<0.001

***

1% PFP

8.73(±0.11)

8.05(±0.03)

<0.001

***

1% CD:IC

8.70(±0.05)

7.94(±0.07)

<0.001

***

2% PFP

8.85(±0.02)

8.02(±0.004)

<0.001

***

2% CD:IC

8.96(±0.06)

8.14(±0.04)

<0.001

***

4% PFP

9.13(±0.08)

8.53(±0.01)

<0.001

***

4% CD:IC

8.98(±0.08)

8.66(±0.04)

<0.001

***

RT, Surfactant
PBS Control

8.50(±0.09)

7.84(±0.08)

<0.001

***

1% CD

8.60(±0.03)

7.80(±0.05)

<0.001

***

2% CD

8.48(±0.10)

7.98(±0.02)

<0.001

***

4% CD

8.67(±0.02)

8.16(±0.01)

<0.001

***

1% PFP

8.73(±0.03)

8.26(±0.04)

<0.001

***

1% CD:IC

8.73(±0.03)

8.36(±0.01)

<0.001

***

2% PFP

8.89(±0.05)

8.47(±0.01)

<0.001

***

2% CD:IC

9.32(±0.04)

8.91(±0.04)

<0.001

***

4% PFP

9.41(±0.14)

9.29(±0.05)

0.49

x
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4% CD:IC

9.63(±0.03)

9.54(±0.04)

0.87

x

37°C, No Surfactant
PBS Control

6.806(±0.0333)

6.66(±0.01)

0.76

x

1% CD

6.88(±0.02)

6.78(±0.02)

0.83

x

2% CD

6.90(±0.02)

6.78(±0.02)

1.09

x

4% CD

7.12(±0.04)

6.93(±0.09)

0.93

x

1% PFP

7.10(±0.07)

6.91(±0.02)

0.83

x

1% CD:IC

7.29(±0.04)

7.13(±0.02)

0.99

x

2% PFP

7.34(±0.08)

7.22(±0.01)

0.79

x

2% CD:IC

7.41(±0.02)

7.32(±0.01)

0.66

x

4% PFP

7.63(±0.01)

7.40(±0.01)

0.63

x

4% CD:IC

7.87(±0.02)

7.71(±0.01)

0.30

x

37°C, Surfactant
PBS Control

6.92(±0.04)

6.82(±0.01)

0.02

*

1% CD

6.95(±0.05)

6.92(±0.04)

0.99

x

2% CD

6.94(±0.07)

6.88(±0.02)

0.58

x

4% CD

7.07(±0.0270)

6.84(±0.02)

<0.001

***

1% PFP

7.14(±0.02)

7.04(±0.04)

0.02

*

1% CD:IC

7.28(±0.03)

7.27(±0.01)

1

x

2% PFP

7.60(±0.002)

7.51(±0.02)

0.07

x

2% CD:IC

7.69(±0.02)

7.61(±0.01)

0.17

x

4% PFP

7.91(±0.02)

7.75(±0.01)

<0.001

***

4% CD:IC

7.95(±0.005)

7.92(±0.02)

1

x
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Appendix 7-5: Statistical analysis for dissolved oxygen measured in PBS at 37 °C in
the presence of 3D electrospun fibrous mats compared to a PBS control. Dissolved
oxygen was measured with a fiber optic probe. Data are means ± SD for experiments
performed in triplicate. Statistical significance: x indicates p>0.05, * indicates p≤0.05.
*** indicates p≤0.001.
DO (mg/L)

Day

p value

Significance

DO (mg/L)

PCU

p value

Significance

PCU-CD:IC

1

6.43(±0.22)

0.34

x

8.47(±0.48)

0.18

x

3

7.82(±0.08)

0.99

x

8.07(±0.32)

0.78

x

5

8.14(±0.26)

0.68

x

9.71(±0.32)

<0.001

***

7

8.26(±0.35)

0.45

x

10.9(±0.53)

<0.001

***

10

7.04(±0.96)

1.00

x

9.38(±0.26)

<0.001

***

14

7.93(±0.19)

0.94

x

9.63(±0.62)

<0.001

***

Day

PCU

PCU-CD:IC

1

6.57(±0.20)

0.59

x

8.52(±0.80)

0.16

x

3

8.38(±0.18)

0.32

x

9.02(±0.42)

0.01

*

5

8.35(±0.33)

0.35

x

9.94(±0.29)

<0.001

***

7

8.24(±0.87)

0.52

x

9.62(±0.45)

<0.001

***

10

7.94(±0.42)

0.94

x

9.51(±0.21)

<0.001

***

14

8.40(±0.12)

0.29

x

10.0(0.46)

<0.001

***

Appendix 7-6: Statistical analysis comparing dissolved oxygen measured in the
presence of 3D electrospun fibrous mats fabricated from PCU and PCL containing αCD/PFP CD:ICs in PBS at 37 °C. Dissolved oxygen was measured with a fiber optic
probe. Data are means ± SD for experiments performed in triplicate. Statistical
significance: x indicates p>0.05, * indicates p≤0.05. *** indicates p≤0.001.
Day
1
3
5
7
10
14

PCU-CD:IC
8.47(±0.48)
8.07(±0.32)
9.71(±0.32)
10.9(±0.53)
9.38(±0.26)
9.63(±0.62)

PCL-CD:IC
8.52(±0.80)
9.02(±0.42)
9.94(±0.29)
9.62(±0.45)
9.51(±0.21)
10.0(0.46)

p value
1
0.37
1
0.07
1
0.99

Significance
x
x
x
x
x
x
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Appendix 7-7: Preliminary Cell Studies
Materials and Methods
Cell Culture on 3D Scaffolds
Three-dimensional polymer scaffolds with an area of approximately 3.2 cm2 were cut from
PCU, PCU-CD:IC, PCL, and PCL-CD:IC electrospun fibrous mats. The scaffolds were
exposed to UV irradiation for 1 hour per side for disinfection. The mats were transferred
to culture plates, rinsed once with Hank’s Balanced Salt Solution (HBSS), and soaked in
fresh HBSS overnight for conditioning (Invitrogen Canada Inc., Burlington, ON) at RT.
Mouse embryonic fibroblasts (NIH-3T3 cell-line) were seeded directly on the surface of
the scaffolds, at a density of 100,000 cells/scaffold, affixed to the bottom of the well using
an O-ring. The cells were maintained in a humidified incubator at 37 °C and 5 % CO2 after
adding with 0.5 mL/well of advanced DMEM (GIBCO® Invitrogen, Burlington, ON,
Canada) containing 5 % FBS, 1 % antibiotics, and 0.2 mM L-glutamine.

Cytotoxicity Assay
Cell toxicity and proliferation were quantified by colorimetric assays of the metabolic
activity of viable cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (Vybrant® MTT Cell Proliferation Assay Kit, Invitrogen Canada Inc.).
The MTT tetrazolium dye is reduced to insoluble formazan salts in correspondence to the
activity level of NADPH-dependent oxidoreductase enzymes of metabolically active cells
producing a purple colour. The concentration of the formazan salts, and therefore metabolic
activity level of the cells present, is determined using optical density at λ = 570 nm.

At time points of 1, 3, 5, and 7 days, the spent culture media was aspirated and replaced
with 300 µL of fresh phenol-red free DMEM (GIBCO® Invitrogen, Burlington, ON,
Canada) followed by MTT (30 μL, Component A) and allowed to incubate for 4 hours.
Sodium dodecyl sulphate in dilute acid (300 μL, Component B) was added to the wells to
solubilize the water insoluble formazan salts upon thorough mixing and incubation
overnight. The resultant coloured solution was quantified using a BioTek EL307C
multiplate reader (BioTek Instruments, Inc., Winooski, VT) at the maximum absorbance
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wavelength of the formazan solution (570 nm). The results of the MTT assays are presented
as the mean ± standard deviation for experiments conducted with 3 replicates.

Cytotoxicity Assay and Cell Spreading
The ultimate application of the 3D fibrous scaffolds incorporating CD:ICs prepared with a
PFP is to enhance oxygen delivery to cells seeded on the construct during in vitro
maturation. It was therefore necessary to evaluate the interaction of the materials with cells
to ensure their cytocompatibility. For this, the 3D mats were fixed to the bottom of a tissue
culture plate well, and cytotoxicity and cell proliferation were analyzed using MTT assays.
A mouse fibroblast cell line (NIH-3T3) was used to evaluate the effect of the CD:ICfunctionalized fibers on cell viability and metabolic activity over a time period of 7 days.
The CD:IC-functionalized scaffolds were compared to PCU or PCL scaffolds without any
modification as a control. As shown in Figure 7-1, there is no significant difference in the
metabolic activity observed on the CD:IC-functionalized scaffolds as compared to the
unmodified controls. Both PCU and PCL are well-known biocompatible materials,1 so the
similarity in metabolic activity suggests that, at the concentrations tested, the CD:ICfunctionalized materials were not cytotoxic. The differences observed between the PCUand PCL-based materials is potentially due to the different amount of CD:IC incorporated
within the polymer material. It was possible to incorporate 50 % (w/w) CD:IC in the PCU
scaffold while maintaining adequate fiber morphology, but only 15 % (w/w) CD:IC was
incorporated in the PCL scaffold. This data could indicate that there is a threshold above
which the CD:IC becomes toxic to fibroblasts. Moreover, if there is any uncomplexed CD
in the electrospinning solution, solvent could be retained in the cavity leading to
cytotoxicity. Further studies are necessary to elicit the effect of the α-CD/PFP complex on
cytotoxicity and proliferation, especially over the long-term.
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*

Figure 7-1: Fibroblast metabolic activity as determined by MTT assay over a 7 day
period. Metabolic activity on CD:IC-functionalized materials are compared to that
on the unmodified base polymer. The data are presented as mean ± standard
deviation. Experiments were carried out in triplicate.
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